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ABSTRACT 
Background 
Kidney cancer is the 12th most common malignancy worldwide, accounting for 
over 400,000 new cases in 2018 (1). As renal cell carcinoma (RCC) incidence 
and mortality, as well as treatment patterns, vary widely in Europe, to plan 
strategies for the future, we need to comprehend the current situation in 
Finland.  
Accurate prognostic tools are essential for detecting cancers amongst the 
tumours noted in imaging studies and choosing optimal treatment for cancer 
patients. The Tumor, Node, Metastasis (TNM) staging system and 
International Society of Urologic Pathology (ISUP)/Fuhrman grading system 
are the most commonly used prognostic parameters for RCC. Currently, risk 
stratification relies on prognostic nomograms or risk stratification tools 
combining clinical, anatomical and histopathological data. However, these 
models have well-known limitations.  
Treatment for RCC is changing. Over the last decades, more incidental 
RCCs were found, and more minor lesions were operated on using less invasive 
techniques. At the opposite end of the disease spectrum, selected metastatic 
RCC patients receive a combined treatment consisting of nephrectomy, 
metastasectomy and oncologic therapies. Surgery for locally advanced and 
metastasised tumours must be justified by the prospect of an improved 
outcome or quality of life. Decisions to operate on metastatic RCCs are 
currently based on expert opinions and nomograms designed for targeted 
therapy survival estimations only. Thus, better prognostic markers and 
diagnostic tools are needed. 
Aims 
The aims of this PhD study were to evaluate the current changes in the clinical 
picture, treatment and outcomes of RCC in Helsinki University Hospital 
district. Further analysis was done to determine the clinical outcomes of 
surgically treated RCC with tumour thrombus and metastasised RCC (mRCC). 
The authors aimed to externally validate the performance of the Leuven-Udine 
(LU) prognostic group model for mRCC and to evaluate the prognostic value 
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of serum concentration of tumour-associated trypsin inhibitor (TATI). The 
performance of renal tumour diameter and parenchymal invasion depth was 
compared with more complex classifications to assess their accuracy in 
predicting the nephrectomy performed. 
Patients and methods 
All patients studied were either suspected to have RCC or had RCC, and the 
majority of patients underwent nephrectomy at the Helsinki University 
Hospital (HUH). There were 1,719 patients with tumours suspected of RCC 
evaluated in four periods from 2006 to 2016 for clinical characteristics and 
treatments offered. From 2006–2014, 142 RCC patients with tumour 
thrombus (TT) were operated on at HUH. In total, using computed 
tomography (CT) or magnetic resonance imaging (MRI) images of 915 
patients, tumour maximum diameter, depth of invasion, Preoperative Aspects 
and Dimensions Used for an Anatomical (PADUA) score and Renal Tumour 
Invasion Index (RTII) were estimated. There were 97 patients with metastatic 
RCC undergoing surgery for metastases. Preoperative and postoperative serum 
levels of tumour associated trypsin inhibitor (S-TATI) of 132 RCC patients 
were determined by time-resolved immunofluorescence assay in 2006-2010. 
Main results and conclusions 
During the study period, the proportions of frail and co-morbid patients 
increased significantly as did the percentage of small (diameter ≤4 cm) and 
asymptomatic tumours. The use of surveillance as treatment increased 
significantly while the use of cytoreductive nephrectomies (CNs) decreased to 
54%. However, CN combined with tyrosine kinase inhibitors remained the 
primary option in patients with metastatic RCC. However, the changing 
landscape of RCCs has already affected and will increasingly affect the 
treatments given. 
For RCC patients with TT, no statistically significant difference in survival 
was found amongst the different levels of the venous extension. The prognosis 
for operated RCC patients with TT was good in the absence of papillary 
histology of primary tumour, lymphoid or distant metastases. Surgery remains 
a feasible option for selected patients in the era of modern oncologic therapy. 
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In predicting the type of nephrectomy, partial or radical, the simple 
measurements of tumour diameter and parenchymal invasion, were superior 
to the more complex classification. Hence, all of them were significant 
predictors for nephrectomy type. Our results recommend that potential 
anatomical classifications should be tested against these user-friendly 
measurements, diameter and parenchymal invasion. 
Overall survival (OS) was more favourable for patients undergoing 
complete metastasectomy than patients with non-complete metastasectomy 
and time to systemic therapy was longer. Patients with skeletal metastases had 
shorter survival than patients with other metastatic sites whereas patients with 
lung metastases had the most favourable prognosis. In this study population, 
the performance of the LU prognostic group model could not be validated. 
Despite the abundant amount of inauspicious prognostic factors in our patient 
cohort, survival rates were reasonable.  
Significant associations with preoperative S-TATI and Chronic Kidney 
Disease Stage (CKD grade), tumour stage, lymph-node involvement, 
metastatic status and preoperative C-reactive protein (CRP) level were noted. 
S-TATI, as a continuous variable, however, significantly predicted OS and 
cancer-specific survival (CSS). Prognostic significance of S-TATI should be 
further studied in larger patient cohorts and prospective settings. 
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1 INTRODUCTION 
Renal cell carcinoma (RCC) is the most lethal urological malignancy; however, 
reliable prognostic tools to recognise the ‘killer tumours’ from indolent ones 
are lacking. Being a highly heterogenic disease, the clinical course of RCC is 
strikingly unpredictable. 
As up to half of newly diagnosed RCCs are incidental findings (2, 3), we are 
often faced with the clinical challenge of an unclassified tumour susceptible to 
malignancy which is found in an imaging study. Peak incidence of RCC is from 
60 to 70 years of age, meaning that RCC patients are often frail, have co-
morbidities and a limited life expectancy. Therefore, operations for indolent or 
slowly progressing tumours may easily turn into overtreatment. Renal tumour 
biopsies (RTBs) are used to distinguish malignant tumours from benign ones. 
The sensitivity of an RTB for detecting renal malignancy is excellent in 
experienced centres (93-99.5%) (4, 5), but the accuracy of defining the grade 
is poor (67%) (4). Although severe complications associated with RTBs are rare 
(4), there is a definite need for less invasive and more precise tools to predict 
the course of yet unclassified renal tumours. 
The five year overall survival (OS) for all RCCs was reported to be as low as 
40% by a Swedish population-based study and merely 13% for metastatic RCC 
(6). Of local tumours operated on with curative intention, 20-40% commonly 
recur (7). When considering who benefits from nephrectomy or 
metastasectomy, estimating survival is important. The tumour, node and 
metastasis (TNM) classification is one of the most common and robust 
predictors of oncological outcomes (8). TNM classification and other 
prognostic factors for RCC, such as Fuhrman grade, tumour necrosis, 
histologic subtype and performance status of the patient, are not sufficiently 
accurate prognosticators when used alone (9). Hence, these prognostic factors 
are combined to numerous prognostic models or nomograms both for localised 
and metastatic RCCs. The follow-up recommendations and treatment 
decisions are based on these nomograms and models estimating recurrence 
and survival. Still, as clinicians and researchers, we are in great need of more 
accurate prognostic information to facilitate patient counselling, plan 
individual surveillance schemes and select optimal treatments for each patient 
(9). 
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To improve the prognostic accuracy, the further research and development 
of prognostic biomarkers has become a priority. The increased understanding 
of gene technology, proteomics, molecular biology and immunology of cancer 
has raised great hope for finding a ‘true prognostic biomarker’. Despite the 
exhaustive efforts made in marker research, no molecular biomarker has been 
able to significantly improve the prognostic accuracy of existing models (10). 
Surgery is always prone to complications, and complication rates vary 
amongst centres and procedures. Knowing the results of one’s own centre is a 
benefit when planning more complicated surgery. After recent improvements 
in targeted therapy and immuno-oncology, doubts have been raised about the 
role and sequence of surgery in metastasised cases (11, 12). As metastasectomy 
or cytoreductive nephrectomy may also be used for palliation, the risk of 
complications, the recovery time from surgery and delay in commencing 
systematic treatments must be tolerable. For local tumours, mini-invasive 
surgery is the treatment of choice in all T1 tumours (13) as the oncologic safety 
of partial nephrectomy (PN) seems to be similar when compared with radical 
nephrectomy (RN) (13). Still, 22% of pT1a tumours are removed by RN in 
Northern European countries (14), inferring that more than just the diameter 
affects our decisions. 
 15 
2 REVIEW OF LITERATURE 
2.1 EPIDEMIOLOGY OF RENAL CELL CARCINOMA 
RCC accounts for 2-3% of all cancers (15, 16), representing the ninth most 
common cancer in men and the sixteenth in women (17). For men, the lifetime 
risk for developing kidney cancer is about 1 in 48. In Finland, the reported 
number of new cases of RCC in 2018 was 1,010, ranking 10th in all newly 
diagnosed cancers (18).  
 
Figure 1 Estimated age-standardized rates of incidence for both sexes (per 100,000 
persons) in 2018. In developed countries, the incidence is generally higher than 
in developing countries. Reprinted with the permission from the World Health 
Organization. 
The number of incidental RCCs, usually smaller and of lower stage, have 
increased due to the increased use of imaging techniques. The proportion of 
small renal masses (SRMs) is currently up to 40% of overall incidence (19). 
Over the last decade, the RCC incidence has been rising worldwide, although 
this is less pronounced in women (18). However, a great disparity exists 
concerning RCC incidence globally (Figure 1). The incidence of RCC is highest 
in Western countries (16, 18). Differences are also profound in Europe: male 
incidence in Sweden and Malta is as low as 7.1/100,000 but is 22/100,000 in 
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the Czech Republic (16). Amongst the countries of Northern Europe, only in 
Finland and Estonia is male RCC incidence stabilised (18) (Figure 2). 
 
Figure 2 RCC incidence by age group in Finland from 1953 to 2018. Data from Finnish 
Cancer Registry. https://tilastot.syoparekisteri.fi/syovat, data from 2020-04-02, 
version 2020-04-17-004. Reprinted with the permission of Finnish Cancer 
Registry. 
Kidney cancer is the 16th most common cause of death worldwide. In 
Northern Europe, Scandinavia, North America and Australia, mortality has 
trended downward since the 1990s (Figure 3), while mortality has increased in 
Croatia, Greece, Slovenia and Portugal (16, 18, 20). Indeed, a worldwide gap in 
survival rates between high resource and low resource countries does exist and 
might even be widening following the introduction of immunotherapy (Figure 
4).   
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Figure 3 Age-standardised mortality rate (Finland 2014) per 100,000 for males and females 
from 1954 to 2018. Mortality started to decline in the 1990s. Data from Finnish 
Cancer Registry. https://tilastot.syoparekisteri.fi/syovat, data from 2020-04-02, 
version 2020-04-17-004. Reprinted with the permission of Finnish Cancer Registry. 
 
Figure 4 Estimated age-standardized rates of mortality (world standard population) for 
both sexes (per 100,000 persons) in 2018. The estimated age-standardised 
mortality rate in Finland equals the Danish figure (2.7/100,000) and is higher than 
in Sweden and Norway (2.3/100,000). Reprinted with the permission from the 
World Health Organization. 
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2.2 ETIOLOGY AND RISK FACTORS OF RENAL CELL 
CARCINOMA 
Known risk factors for RCC are age, with peaks at 60-70 years, and gender, 
with a 1.5:1 male predominance. Common risk factors found in epidemiological 
studies include cigarette smoking (21), obesity (22), hypertension (21) and 
greater adult attained height (1). However, the importance of these risk factors 
may be biased by incidental cancer detection in imaging done due to illnesses 
associated with these risk factors (23). The presence of kidney disease, viral 
hepatitis, urinary stone in male patients and continuous use of paracetamol or 
non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) seem to increase 
the risk of RCC (21, 24). Having a first-degree relative with RCC has been 
associated in meta-analysis with a 2.2-fold and, in case-control analysis, a 4.3-
fold significantly increased risk for RCC, 95% CI [1.6-2.9] and [1.6-11.9], 
respectively (25). 
Kidney transplantation, end-stage renal disease and dialysis predispose 
patients to RCC (26-28). Several hereditary syndromes elevate the risk of RCC, 
accounting for 4% of all RCCs (25). Von Hippel-Lindau (VHL) disease, Birt- 
Hogg-Dubé syndrome (BHD), hereditary leiomyomatosis and renal cell cancer 
(HLRCC), hereditary papillary renal cancer (HPRC) and tuberous sclerosis 
complex (TSC) are the five most common autosomal dominantly inherited 
syndromes with distinct clinical manifestations and genetic alterations (29). 
However, most cases of TSC occur as sporadic cases, due to de novo mutation.  
Physical activity and consumption of cruciferous vegetables associate with 
a lower risk of RCC (30, 31) as well as moderate alcohol consumption relative 
to abstinence (1, 32).  
2.3 DIAGNOSING RENAL CELL CARCINOMA 
2.3.1 CLINICAL PRESENTATION 
Being located retroperitoneally and surrounded by fat, tumours of the kidney may 
enlarge significantly without presenting any symptoms. Due to the lack of early 
warning signs, as many as 25-30% of RCCs have already metastasised by the time 
of diagnosis (33). However, the recent population-based data from Sweden show 
the percentage of synchronous metastatic RCC to be as low as 19% (2). 
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The ‘classic triad’ of RCC, which includes abdominal pain, haematuria and 
palpable mass in the flank or abdomen, is especially rare today. Earlier, 6-10% 
of patients presented this triad (34, 35). Currently, up to 50% of RCC is 
detected incidentally (2, 3). However, the disease is sometimes accompanied 
by paraneoplastic symptoms such as fever, malaise, erythrocytosis and 
hypercalcemia.  
No laboratory examinations, serum or urine are helpful in diagnosing 
whether a renal cell carcinoma exists. However, laboratory parameters, i.e. 
haemoglobin, neutrophils, thrombocytes, lactate dehydrogenase and calcium, 
are used to estimate prognosis of metastasised RCC. 
2.3.2 RADIOLOGICAL EXAMINATIONS 
Most renal masses are primarily diagnosed by imaging. Ultrasound imaging 
often raises suspicion about RCC, which is then followed by further imaging 
with computed tomography (CT) or magnetic resonance imaging (MRI). The 
paramount criterion for malignancy is the enhancement of contrast material 
within the tumour (36). An increase of 15 or more Hounsfield units (HUs) 
indicates solid tissue, which is most often malignant (37). However, fat-free 
angiomyolipomas and oncocytomas cannot be reliably differentiated from 
RCC. Recently, contrast-enhanced ultrasound (CEUS) has been used to 
differentiate cystic lesions from solid ones and has high sensitivity and 
specificity in characterising renal masses (38). For the purpose of staging RCC, 
thorax CT added to renal imaging by CT or MRI is recommended (13). CT of 
head and bone scans are performed only in the presence of symptoms or 
particular signs (13, 39). Position-emission tomography has a low sensitivity 
and specificity for detecting RCC and is not recommended by European 
Association of Urology (EAU) Guidelines (13) . 
RTB is often considered non-necessary if the patient will undergo an 
operation based on radiology (13). Renal biopsies are strongly recommended 
prior to ablative treatment and for matching patients with the best medical 
therapy scheme, and they can be used to guide patient selection to active 
surveillance (13). Use of ultrasound or CT guidance provides similar results 
(40, 41). Even in experienced centres, up to 22% of biopsies are non-diagnostic, 
however (4, 42). Researchers found that the diagnostic rate was lowest when 
there was a long distance (>10 cm) from skin to tumour (73.1%), tumour 
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diameter was smaller than 4 cm (86.2%), enhancement on contrasted CT was 
less than 20 HU (57.9%) or the tumour was cystic (60.2%) (43). Also, biopsies 
of cystic tumours are not recommended (13).  
In the literature, tumour seeding due to biopsy is anecdotal and is supposed 
to be avoided if biopsies are taken using the co-axial technique (4, 5, 44). In 
the co-axial technique, a larger needle, an introducer, is put in contact with 
target lesion and a smaller biopsy needle passes through it, multiple times if 
necessary, to avoid tumour contamination to surrounding tissues. However, a 
recent study by Macklin et al. has indicated that the risk of tumour seeding is 
minor but also real when using the co-axial technique (45). A patient case with 
tumour seeding and local recurrence is presented in Figure 5.  
     
a)                                                                        b) 
Figure 5 Radiological evidence of tumour recurrence after positive nephric margin and 
renal tumour biopsy. a) A preoperative image of left solitary renal tumour. b) 
Postoperative recurrence was noted on the tract of renal biopsy. Figure published 
with the permission of Elsevier: European Urology, 2019, May; 75(5):861-867, 
Macklin et al., ‘Tumour Seeding in the Tract of Percutaneous Renal Tumour 
Biopsy: A Report on Seven Cases from UK Tertiary Referral Centre.’ 
2.3.3 HISTOLOPATHOLOGICAL CLASSIFICATIONS 
RCC originates from renal tubular epithelial cells. RCC, being a highly 
heterogenous disease, comprises several genetic and histological subclasses as 
reported in the 2016 World Health Organization (WHO) classification (46). 
Three predominant subtypes are clear-cell RCC (ccRCC), papillary RCC 
(pRCC) and chromophobe RCC (chroRCC), together accounting for 85-90% of 
all renal malignancies (47). The three most common histologic subtypes and 
their features are presented in Table 1.  
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Oncocytomas comprise 7% of all renal tumours (48). As there are cases 
where oncocytoma has been noted to invade vascular structures and 
perinephric fat, although without altering the benign prognosis of oncocytoma, 
it could be considered as a tumour of a very low potential of malignancy instead 
of a strictly benign tumour (49) (50). Indeed, the EAU recommends that active 
surveillance should be offered as a treatment alternative for biopsy proven 
oncocytomas, as only 64.6% of those remained histologically oncocytomas 
after surgery, while 31% were classified as cancers (51). 
Table 1. The three most common histologic subtypes and their features (52-55). 
ccRCC=clear cell renal cell carcinoma, pRCC = papillary renal cell carcinoma, 
ISUP= International Society of Urological Pathology, Polypromo =PBRM, SETD 
=SET domain, nuclear respiratory factor =NRF, phosphate and tensin homolog 
=PTEN, folliculin =FLCN, succinate dehydrogenase deficient=SDH. Histologic 
pictures are of patients included in the Helsinki University Kidney Tumour 
Database and were photographed by Tuomas Mirtti and Anni Virtanen. 
Tumour histology ccRCC pRCC Chromophobe RCC 
Morphology  
 
 
 
 
 
Fuhrman/ISUP 
grading 
Used Used Not used 
Incidence (%) 75% 10% 5-7% 
Alterations in 
chromosomes 
3p loss (91%) 
5q gain (67%) 
14q loss (49%) 
Type I: Gains of 7, 
8q, 12q, 16p, 17, 20, 
and loss of 9p 
Type II: Gains of 8q, 
loss of 1p and 9p 
Loss of 
chromosomes 1, 2, 6, 
10, 13, 17 and 21 
Gene mutations VHL most common 
(54%) 
PBRM1 (40%) 
SETD2 (13%) 
BAP1 (10%) and 
others 
Type I: MET 
mutations (81%) 
Type II: CDKN2A, 
SETD2 and NRF2  
Low rate of somatic 
mutations. TP53, 
PTEN, FLCN gene 
Hereditary 
syndromes 
VHL, tuberous 
sclerosis, BAP1 
mutant disease, 
SDH-associated 
kidney cancer 
Heredital papillary 
kidney cancer, 
hereditary 
leiomyomatosis and 
RCC and Birt-Hogg-
Dubé 
Birt-Hogg-Dubé 
Average age 64 60  58 
Male: Female ratio 2:1 1.5:1 1.1:1 
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The remaining histologic subtypes are rare, each accounting for 
approximately 1% of total incidence (46). These minor subtypes include 
collecting duct RCCs, medullary RCC, clear-cell papillary RCC, 
microphthalmia-associated transcription factor (MiT) family translocation 
RCCs, hereditary leiomyomatosis and RCC, acquired cystic disease-associated 
RCC, tubulocystic RCC, succinate dehydrogenase-deficient RCC and mucinous 
tubular and spindle cell RCC. Up to 4% of RCCs fail to fit into any of these 
categories and are labelled as unclassified RCCs (52). 
Pathological diagnosis does not only determine the subtypes of RCC, but 
also interprets the nuclear grade, tumour necrosis, lymphovascular invasion, 
sarcomatoid features and invasion to perirenal fat or venous system stage (53). 
2.4 SURVIVAL AND PROGNOSTIC FACTORS 
The clinical course of RCC is variable. After complete, curative-intended, 
surgical resection of local RCC, up to 30% recurred, according to a five-year 
follow-up, after being considered disease-free (56). The most fundamental 
prognosticator is whether the RCC is localised or advanced, at the time of 
diagnosis, as the hazard ratio of cancer-specific survival (CSS) in metastatic 
(M1) disease is 33.23 (95% CI [28.18-39.18]) compared with T1N0M0  disease 
(57). Prognostic factors can be labelled as clinical, anatomical, 
histopathological and molecular. Prognostic models which combine individual 
prognostic factors are needed to predict individual likelihood of recurrence and 
death when counselling patients and selecting patients for adjuvant therapy 
trials. Accurate and easy-to-use prognostic markers and models are needed, as 
detecting cancer as early as possible, finding the ones that will recur and 
deciding the right individual treatment for cancer patients are some of the 
great challenges of medicine today.  
2.4.1 ANATOMICAL PROGNOSTIC FACTORS 
2.4.1.1 TNM classification 
The classic anatomic prognostic system is TNM classification (58) (Table 2). It 
was composed for scientific and clinical use (59). The current TNM 
classification was constructed in 1997 with global consensus (60) and is 
continuously updated by the Union for International Cancer Control. The 
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latest update was done in 2017. Tumour size, invasion of the renal capsule or 
venous system, adrenal involvement, lymph node status and existence of 
distant metastasis, all important prognostic factors, are included in TNM 
staging. The TNM classification is one of the most solid and reliable predictors 
of oncologic outcomes, as OS (Figure 6) and recurrence (8). The TNM 
classification from 2010 divided T2 into T2a and T2b and changed the pT3a 
and pT3b classifications. However, these changes have led to only modest 
improvements in predictive accuracy (8).  
Table 2. TNM Classification 2017 (58). Tumour =T, pathological tumour-node-metastasis 
=pTNM 
T  Primary Tumour 
pTNM Stage 
Group 
TX  Primary tumour cannot be assessed  
T0  No evidence of primary tumour Stage I 
T1  Tumour < 7 cm or less in greatest dimension, limited to the 
kidney 
 
 T1a Tumour < 4 cm or less  
 T1b Tumour > 4 cm but < 7 cm  
T2  Tumour > 7 cm in greatest dimension, limited to the kidney Stage II 
 T2a Tumour > 7 cm but < 10 cm  
 T2b Tumours > 10 cm, limited to the kidney  
T3  Tumour extends into major veins or perinephric tissues but 
not into the ipsilateral adrenal gland and not beyond 
Gerota fascia 
Stage III 
 T3a Tumour grossly extends into the renal vein or its 
segmental (muscle-containing) branches, or tumour 
invades perirenal and/or renal sinus fat (peripelvic fat), but 
not beyond Gerota fascia 
 
 T3b Tumour grossly extends into the vena cava below 
diaphragm 
 
 T3c Tumour grossly extends into vena cava above the 
diaphragm or invades the wall of the vena cava 
 
T4  Tumour invades beyond Gerota fascia (including 
contiguous extension into the ipsilateral adrenal gland) 
Stage IV 
N  Regional Lymph Nodes  
NX  Regional lymph nodes cannot be assessed  
N0  No regional lymph node metastasis  
N1  Metastasis in regional lymph node(s) Stage III              
(T1-3, M0) 
M  Distant metastasis  
M0  No distant metastasis  
M1  Distant metastasis Stage IV             
(Any T, any N) 
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Figure 6 Kaplan‐Meier survival curves for the patients of different TNM subgroups from 
the Surveillance, Epidemiology and End Results (SEER) cohort, affirming the 
clear differences in OS. Figure is reprinted by permission from Creative 
Commons, https://creativecommons.org/licenses/by/4.0/. Cancer Med. 2018 
Nov; 7(11): 5431–5438. Shao et al., ‘Modification of American Joint Committee 
on cancer prognostic groups for renal cell carcinoma’. 
2.4.1.2 Other anatomic systems 
Tumour diameter from the TNM classification (58) has been considered as 
insufficient to guide preoperative planning and to predict the perioperative 
outcome in terms of complications, operative time and renal function. A wide 
range of anatomical scorings has been introduced since 2009 to classify renal 
tumours more accurately, comprising the assessment of size, exo-/endophytic 
properties, measure of invasion, position in kidney and proximity to the 
collecting system and renal sinus. 
The RENAL Nephrometry Score (61) and Preoperative Aspects and 
Dimensions Used for an Anatomical (PADUA) classification (62) are the most 
frequently used and validated systems for guiding the choice of nephrectomy 
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and to predict complications, length of operation and hospital stay (63, 64). 
Other scoring systems are the zonal NePhRO scoring system (65), the surgical 
approach renal ranking (SARR) (66), centrality index (67), the Renal Tumor 
Invasion Index (RTII) (68), diameter-axial-polar (DAP) nephrometry (69), the 
renal tumour contact surface area (CSA) (70) and resected and ischemic 
volume (RAIV) (71), to name a few.  
2.4.2 HISTOLOGICAL PROGNOSTIC FACTORS 
The survival rates for ccRCC are the lowest, followed by pRCC and chroRCC 
(72, 73), but when stratifying histology to tumour grade or tumour stage (T-
stage), the survival rate differences disappear in multivariable analysis, 
indicating that stage and grade determine prognosis more than histological 
subtype (74). Also, pRCCs consist of type 1 and type 2, with the first group 
being of lower grade and of favourable outcome, while latter group’s tumours 
are of higher grade with an increased metastatic potential (75, 76). The 
prognostic difference between this subtyping is however debatable (75). 
Median survival of a rare subtype, carcinoma of the collecting duct, is 13 
months, remarkably lower than for ccRCC, and the majority of tumours (70%) 
have metastasised by the time of diagnosis (77). 
The presence of necrosis, sarcomatoid or rhabdoid features, microscopic 
venous or lymphaneous invasion and invasion in the collecting system are all 
associated with worse outcomes (78). Having a median survival of 4 to 13 
months after diagnosis, sarcomatous carcinoma has a discouraging prognosis 
(79, 80). Of the relevant histological features, sarcomatoid differentiation also 
predicts a worse prognosis in metastatic renal cell carcinoma (mRCC) (81) as 
well as does non-ccRCC histology (82). For patients with rhabdoid features 
containing carcinoma, median survival is slightly better (8 to 45 months) than 
for sarcomatotic features. Rhabdoid features, as independent prognostic 
factors apart from Fuhrman grade, were not found to be associated with higher 
mortality (80, 83). Necrosis, however, is a predictor of CSS (84), recurrence 
(85) and progression to metastasis (86)  
2.4.2.1 Fuhrman/ISUP grading system 
The Fuhrman grading system has been one of most generally agreed upon 
independent prognostic markers for RCC (9, 87). Even though it is the most 
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popular grading system in clinical practice, it is suboptimal at best, and hence, 
it is being replaced by the WHO/International Society of Urological Pathology 
(ISUP) grading system (88). Allocating cancers to different Fuhrman grades 
has not been reliably repeatable. As no recommendation exists for stratifying 
the parameters when contradictory results are noted (75), some pathologists 
grade according to the nuclear prominence only, although this does not follow 
the grading criteria of Fuhrman. The new ISUP grading system is based only 
on nuclear prominence, and should be applied to ccRCC and pRCC, while 
chroRCC should not be graded (75). Table 3 presents the criteria for the ISUP 
and Fuhrman grading systems.  
Table 3. WHO/ISUP grading classification for RCC. Grade is assigned to the highest-
grade cells present, not the most predominant. 
    
ISUP grade 1 ISUP grade 2 ISUP grade 3 ISUP grade 4 
Tumour cell nucleoli 
inconspicuous or 
absent at 400x 
magnification. 
Tumour cell nucleoli 
visible at 400x 
magnification but 
inconspicuous or 
invisible at 100x 
magnification. 
Tumour cell nucleoli 
eosinophilic and 
conspicuous at 100x 
magnification. 
Tumour presenting 
extreme nuclear 
pleomorphism, 
multinucleated cells, 
rhabdoid or 
sarcomatoid 
differentiation. 
Rare 40% of tumours 30-40% of tumours 15% of tumours 
 
    
Fuhrman grade 1 Fuhrman gradus 2 Fuhrman gradus 3 Fuhrman gradus 4 
Nuclear diameter 
small (~10 µm) 
Larger nuclear 
diameter (~15 µm) 
Large nuclear 
diameter (~20 µm) 
Mitoses; bizarre, 
multilobular, 
pleomorphic 
Round uniform 
nucleus 
Irregularities in 
nuclear outline 
Obvious irregular 
outline 
Giant cells, 
macronucleoli, 
extreme irregular 
outline 
Absent, inconspicuous 
nucleoli 
Visible at 400x Prominent at 100x  
Very rare 40% of tumours 30-40% of tumours 15% of tumours 
Data for table received from publication by Delahunt al. Grading of renal cell carcinoma. 
Histopathology. 2019;74(1):4-17. ISUP grading pictures are reformatted and republished 
with the permission of Springer New York: Genitourinary Pathology, 2015. Sukov W. et al. 
Classification of Adult Renal Tumors and Grading of Renal Cell Carcinoma. In: Magi-Galluzzi 
C., Przybycin C. (Eds). Histologic pictures of Fuhrman grading with 40.0 magnification 
received from Tuomas Mirtti and Anni Virtanen.  
 27 
2.4.3 CLINICAL PROGNOSTIC FACTORS 
With RCC, being symptomatic at the time of diagnosis is associated with worse 
survival (89). Moreover, cachexia, anaemia and low physical performance are 
independent markers for poor prognosis (90). The Eastern Cooperative 
Oncology Group (ECOG) or the Karnofsky scale are used to assess the 
performance status, and strongly correlate with prognosis (73).  
Age is not an independent prognostic factor of RCC for surgically treated, 
localised RCC (91), and it is excluded from the commonly used prognostic 
models such as the Stage, Size, Grade and Necrosis (SSIGN) score and 
Memorial Sloan Kettering Cancer Center (MSKCC) nomogram. Age is strongly 
associated with other-cause mortality, meaning that septuagenarians, being at 
high risk for small renal tumour/RCC diagnosis, are also at high risk of other-
cause mortality. 
As age is only a number, the co-morbidity and disability of patients 
potentially play a more significant role when determining the outcomes of 
cancer treatments. In particular, the condition of frailty, meaning when an 
elderly person is a state of major vulnerability due to adverse health status 
changes because of a diminished physiological reserve capacity, is a major 
contributor to health outcomes. Studies of other cancers (92, 93) have pointed 
out that frailty is a predictor of complications after elective surgery, intolerance 
to chemotherapy, progression of disease and worse survival. To the best of my 
knowledge, no studies on the relationship between frailty and RCC exist at this 
point.  
For mRCC patients, there is some evidence that socioeconomic status, older 
age and marital status (widowed, divorced or separated) are associated with 
higher cancer-specific mortality but not with overall mortality (94). However, 
these results may be biased by other factors, e.g. those who are married and 
have better socioeconomic status are more likely to receive cytoreductive 
nephrectomy (CN) (95, 96). 
2.4.4 PROGNOSTIC BIOMARKERS 
Cancer biomarkers are often defined as molecules that raise the suspicion of 
cancer or predict the future prognosis of cancer. But, a biomarker can be any 
medical sign that can be objectively measured and reproduced. Serum 
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prostate-specific antigen (S-PSA) is one of most widely used serum biomarkers 
for cancer, just as body temperature is a common biomarker for fever. Of 
commonly used laboratory markers, low haemoglobin level and high corrected 
serum calcium predict poor survival in patients with advanced RCC (97), and 
they are currently integrated into standard of care survival calculators. In 
addition, for patients receiving targeted therapy, hypertension and 
neutropenia are associated with favourable outcomes (98) and hyponatremia 
with poor outcomes (99). 
Despite the increased interest in molecular biomarkers and the noted 
promising associations with outcomes, no biomarker has yet been externally 
validated or found to clearly improve the accuracy beyond the commonly used 
prognostic factors. Thus, they have not been accepted for use in routine clinical 
practice but are used in experimental settings only. 
2.4.4.1 Markers of hypoxia-induced pathway 
Proneness to inherited RCC arises from genes that participate in regulating 
cellular metabolism. In sporadic ccRCC, some molecular alterations are very 
common: both the inactivation of the von Hippel-Lindau tumour suppressor 
(VHL) gene and the loss of chromosome 3p (site of the VHL gene) are found in 
the majority of cases (100, 101). The VHL gene, which controls oxygen sensing, 
is encoded to protein (pVHL), which targets hypoxia-induced factor 1 alpha 
(HIF-1α). Accumulation of the hypoxia-inducible factors (HIF) leads to 
overexpression of angiogenic factors, platelet-derived growth factor (PDGF) 
and vascular endothelial growth factor (VEGF), which promote 
neoangiogenesis (102). Commonly, HIF is inactive in an oxygenated 
environment but in cancer cells, with VHL mutation, HIF stays active although 
no hypoxemia exists.  
The VHL alterations and HIF-1α have been associated with both better 
(103) and worse survival (104). High carbonic anhydrase IX (CAIX), a HIF-1 α 
regulated protein, has been demonstrated to predict better prognosis (105). 
VEGFs, working as regulators of angiogenesis, have been associated with worse 
survival (106). The best known stimulative and inhibitive pathways for RCC 
are presented in Figure 7. 
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Figure 7 Biologic pathways and markers in renal cell carcinoma. AKT/PKB = akt/protein 
kinase B (gene); CAIX = carbonic anhydrase IX; EGF = endothelial growth factor; 
ERK = extracellular signal-regulated kinase; GF = growth factor; GFR = growth 
factor receptor; HIF = hypoxia-induced factor; MEK = methyl ethyl ketone; MMP 
= matrix metalloproteinase; mTOR = mammalian target of rapamycin; PDGF = 
platelet-derived growth factor; PDGFR = platelet-derived growth factor receptor; 
PTEN = phosphatase and tensin homolog; VEGF = vascular endothelial growth 
factor; VEGFR = vascular endothelial growth factor receptor; VHL = Von Hippel-
Lindau. Republished with the permission of Elsevier, European Urology 2011 
Oct;60(4):644-61. Sun, ‘Prognostic Factors and Predictive Models in Renal Cell 
Carcinoma: A Contemporary Review’. 
2.4.4.2 Immunological markers 
Programmed death-ligand 1 (PD-L1), a ligand on a tumour cell binding to 
programmed death-1 (PD-1) receptor on activated T cells and assumedly 
preventing T cell-mediated tumour killing, is a potential biomarker for PD-
1/PD-L1 blockage therapy. Overexpression of PD-L1, as seen in 30% of RCC 
patients, correlates with worse survival (107, 108). There is some evidence to 
support that PD-L1 expression correlates with higher response rates to anti-
PD-L1 therapy at least in melanoma, but results are less clear for RCC (109). 
Many other immunological markers, as tumour DC8 T-cell density and PD-L2 
expression, are actively being studied (110-112) . 
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2.4.4.3 Inflammatory markers of RCC 
Some tumours are heavily infiltrated by immune cells of the host, and this 
process seems to mimic inflammatory responses of normal tissue (113). 
Previously, this immune reaction was seen as an attempt to erode tumours. 
However, currently, the inflammation process is considered to have the 
paradoxical effect of facilitating the tumour growth and progression (114). 
Inflammation is sometimes present in the earliest stages of progression from 
neoplasia to cancer (115, 116), suggesting that inflammation laboratory exams 
are possible prognostic markers.  
A meta-analysis by Hu et al. noted that elevated C-reactive protein (CRP) 
correlated with poorer CSS and OS (117). The new and promising inflammation 
marker, neutrophil-lymphocyte ratio (NLR), was found to be associated with 
poorer prognosis in a recent meta-analysis (118). Elevated platelet and 
neutrophil counts are also suggested to be independent predictors for poor 
prognosis (119). In addition, the C-reactive protein to albumin ratio has been 
associated with worse OS and disease-free survival (DFS) in a recent meta-
analysis (120).  
Consequently, there is still interest in searching for other acute phase 
reactants that have a prognostic impact for RCC, such as lactate dehydrogenase 
(LD) (121) and tumour-associated trypsin inhibitor (TATI) (122, 123). TATI, a 
6-kDa peptide, occurs in high concentrations in the pancreas and pancreatic 
fluid and in several tumours. As pancreatectomised patients have normal TATI 
concentrations (124), the liver is considered as a main source of TATI (122). 
Increased serum levels are noted in renal, ovarian, colorectal, bladder and 
pancreatic cancer and are associated with adverse outcomes (122, 123, 125). 
Renal excretion removes TATI from circulation. When renal dysfunction 
exists, serum TATI (s-TATI) becomes markedly elevated (126). The TATI 
molecule is shown in Figure 8. 
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Figure 8 Ribbon diagram of recombinant TATI molecule as visualised by the Protein 
Workshop program with surface features. Reprinted with the permission of 
Elsevier: Clinica Chimica Acta, 2014 Apr 20;431:260-9, Itkonen et al., ‘TATI as a 
biomarker’. 
Inflammatory markers are widely available, already implemented in clinical 
practice as markers of infection and inexpensive to use; thus, they are ready to 
be introduced first in research settings and then in clinical practice. 
2.4.4.4 Other markers of RCC 
Results concerning ribosomal protein S6, phosphatase and tensin homolog 
(PTEN) and mammalian target of rapamycin (mTOR) are few, whereas 
expression of p53, Ki-67 and surviving and matrix metalloproteinases seems 
to be associated with impaired prognosis (105). However, BioScore, a 
combination of Ki-67, surviving and B7-H1, was recently externally validated, 
and it did not improve the prognostic accuracy of the SSIGN score (127). Serum 
microRNAs (miRNAs), especially miR21 and miR126, have shown promising 
preliminary results predicting prognosis in RCC (128).  
2.4.5 PROGNOSTIC SYSTEMS AND NOMOGRAMS 
Even the most important established prognostic factors, TNM stage and 
Fuhrman grade, are not sufficiently reliable prediction tools on their own, and 
therefore, there has been a growing call for other prognostic systems. The term 
‘prognostic model’ is used for the clinical prediction model, predictive model 
or prediction index. A nomogram is a graphic illustration of a multivariable 
prognostic model and meant to be used for evaluating patients’ individual risks 
and outcomes at certain time points (129). Usually, the TNM stage is included 
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in all models. The competence of a model is estimated by measuring 
discrimination using the concordance index (C-index) or area under the curve 
(AUC). Mathematic values of discrimination vary from pure hazard (0.5) to 
perfect prediction (1.0). However, no recommendation of an acceptable level 
of accuracy for allowing models to be introduced to clinical practice exists. 
2.4.5.1 Prognostic systems and nomograms in localised disease 
The first models to predict recurrence, the Kattan nomogram (130) and 
Cindolo model (89), included clinical presentation (asymptomatic vs 
symptomatic) at the time of diagnosis. More current models have excluded 
symptoms as the presentation of RCC has changed completely. Currently, up 
to 60% patients are asymptomatic (131), while two decades ago, when Cindolo 
model was introduced, up to 62% of patients were symptomatic at the time of 
diagnosis. (89) 
Prognostic models that predict CSS, such as the SSIGN score (84) and the 
Karakiewicz nomogram (132), including all TNM stages, usually report better 
discrimination than models excluding the metastatic patients, since the 
metastatic stage is the most powerful prognosticator of CSS. The SSIGN score 
and Karakiewicz nomogram have a report accuracy of over 82-88% (133, 134) 
and 87-89% (132), respectively, thus being superior to the TNM stage alone 
(77%) (135). Despite the better (135, 136) discrimination, the models including 
all stages are mainly used for research purposes only because the endpoint 
(CSS) for such a variety of diseases should not guide clinical decision-making.  
The Leibovich prognostic score (86) and University of California Integrated 
Staging System (UISS) (136) are the most generally used postoperative 
prognostic systems. The original purpose of the UISS score was to assess 
survival (136), but after few years, the UISS score was adopted to estimate 
recurrence-free survival (56), while the Leibovich score was used to estimate 
the metastasis-free survival. The Leibovich includes N+ patients and only 
ccRCC, but the UISS considers N+ patients as metastatic and accepts all RCC 
patients. The most common prognostic models both for local and metastasised 
RCC are shown in Table 4. 
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Table 4. Most commonly used prognostic models for both local and metastasised RCC 
presenting studied outcomes and variables included.  
Prognostic models and studied outcomes 
 Localised disease Metastatic disease 
 Leibovich 
prognostic 
score 
UISS SSIGN Postoperative 
Karakiewicz 
model 
MKSCC 
prognostic 
system 
Heng 
model 
Studied 
outcome 
Metastases-
free survival 
Recurrence-
free survival 
CSS CSS OS OS 
Tumours 
accepted 
ccRCC RCC ccRCC RCC RCC RCC 
 
Variables       
TNM stage ✔ ✔ ✔ ✔   
ECOG 
performance 
status 
 ✔     
Karnofsky 
performance 
status 
    ✔ ✔ 
RCC related 
symptoms 
   ✔   
Fuhrman 
grade 
✔ ✔ ✔ ✔   
Tumour 
necrosis 
✔  ✔    
Tumour size ✔  ✔ ✔   
Delay 
between 
diagnosis 
and 
treatment 
    ✔ ✔ 
LDH     ✔  
Corrected 
calcium 
    ✔ ✔ 
Haemoglobin     ✔ ✔ 
Neutrophil 
count 
     ✔ 
Platelet count      ✔ 
Data from Volpe et al. Prognostic factors in renal cell carcinoma. World J Urol. 
2010;28(3):319-27. 
The UISS divides patients into three risk groups: high, intermediate and 
low risk of recurrence, with the five-year recurrence rates being 90.4%, 61.8% 
and 41.9% (56), respectively, and the externally validated accuracy being 80% 
(137). The postoperative follow-up protocol recommended by the EAU 
guidelines is based on UISS risk groups (13). The recurrence usually emerges 
in the first five years following surgery. However, patients with higher UISS 
risk cancer were found to experience recurrence sooner, as median time to 
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recurrence in high, intermediate and low risk groups were 9.5 months (mean 
21.9 ± SD: 26.2), 17.8 months (mean 25.5  ± SD: 23.9) and 28.9 months (mean 
26.5 ± SD: 17.1), respectively (56). In addition, in a RECUR database analysis, 
52.8% (n=28) of Leibovich low-risk patients recurring in a five-year follow-up 
time, 37.1% (n=39) of intermediate risk and 30.5% (n=39) of high-risk patients 
were considered potentially curable at the time of recurrence (138).   
2.4.5.2 Prognostic systems and nomograms for 
metastasised disease 
The earliest version of MSKCC prognostic model dates back to 1999 (139), and 
was updated in 2002 and 2004 (97, 140). In the era of interferon-α, high serum 
corrected calcium, high serum lactate dehydrogenase (LDH), low 
haemoglobin, low Karnofsky performance status and absence of prior 
nephrectomy were all recognised to be independent markers for poor 
prognosis (139). They all, except the absence of prior nephrectomy, combined 
with delay between diagnosis and treatment, have also continued to be 
markers of worse OS after the introduction of tyrosine kinase inhibitor (TKI) 
therapy. The importance of performance status assessed by the ECOG scale or 
Karnofsky index must be highlighted, as it is the most important patient-
derived prognostic factor in mRCC. Criteria for grading the ECOG scale and 
Karnofsky index are presented in Table 5. 
The MSKCC model is still used in recommendations of the EAU for CN, for 
example; however, as it was developed before the targeted therapy era, it is 
considered outdated by some (10). Choueiri et al. combined prognostic factors 
to predict progression-free survival after targeted therapy (141).  
Heng et al. used the International Metastatic Renal Cancer Database 
Consortium (IMDC) data and developed Choueiri’s model, proposing six 
prognostic factors for OS and dividing patients into three prognostic groups 
(poor, intermediate and good prognosis). The median OS for poor-risk, 
intermediate-risk and low-risk groups were determined to be 7.8, 22.5 and 
43.3 months, respectively (142). 
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Table 5. Comparison of ECOG/WHO scoring system versus the Karnofsky scoring 
system. 
ECOG scoring system versus the Karnofsky scoring system 
ECOG/WHO score Karnofsky score 
Asymptomatic,  
fully active,  
no restrictions 
0 
Normal,  
no evidence of disease 100 
Able to perform normal activity with 
only minor symptoms 90 
Symptomatic, restricted in 
strenuous activity but 
completely ambulatory  
Can carry out work 
1 
Normal activity with effort 80 
Able to care for self but unable to do 
normal activities 70 
Symptomatic, ambulatory >50% 
of the time  
Capable of self-care 
2 
Requires occasional assistance, 
cares for most needs 60 
Require considerable assistance 50 
Symptomatic, ambulatory <50% 
of the time  
Capable of limited self-care only 
3 
Disabled, requires special 
assistance 40 
Severely disabled 30 
Confined to chair or bed 
No self-care 
4 
Very sick, requires active support 20 
Moribund 10 
 
Currently, evidence-based recommendations, such as the EAU Guidelines, 
use the IMDC model when targeted therapy is concerned (13). The external 
validation of the IMDC model has shown somewhat similar concordance 
indices for both the IMDC and MSKCC models at 0.664 and 0.657, 
respectively, proving that the MKSCC model is still valid (142). The use of these 
prognostic models is widespread and highly recommended because they are 
the best available. As the majority of known prognostic markers have already 
been tested in different combinations, to gain better discriminancy, the current 
prognostic systems with clinical factors need to be reinforced with novel 
prognostic biomarkers. 
2.4.6 COMPLETE RESECTABILITY AND SURGICAL RESULTS 
Traditional surgical standards demand that there must be a clear margin of 
healthy tissue surrounding the tumour which is removed with the tumour. 
Partial resections, especially enucleations, have challenged this way of 
thinking. Enucleation means blunt dissection along the capsule with no visible 
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layer of normal tissue covering the tumour. Also, in partial resections, the 
healthy tissue margin has been getting smaller. Recently, a meta-analysis 
confirmed that enucleation is as safe as PN concerning progression-free 
survival (PFS) and CSS in a relatively short follow-up time (7.2-54.4 months in 
studies of meta-analysis) and in T1 tumours (143, 144). 
Positive surgical margins (PSMs), usually meaning that cancer cells are 
present in an inked surface, is seen as a risk of oncologic failure, recurrence or 
metastasis. Avoiding PSM is of paramount importance in all cancer surgery. 
However, results are confusing. Some studies have argued that PSM might be 
prognostically significant only with aggressive cancers, if at all (145). Yet, some 
recent studies have been able to demonstrate PSM to be a significant factor 
predicting recurrence (146). The role of PSMs remains debatable, but until 
more conclusive evidence exists, they should be vigorously avoided. 
2.5 TREATMENT OPTIONS FOR LOCAL AND LOCALLY 
ADVANCED RENAL CELL CARCINOMA 
2.5.1 ACTIVE SURVEILLANCE 
More widespread use of imaging has led to an increasing number of 
incidentally diagnosed SRMs. Non-symptomatic tumours, less than 4 cm in 
size, are considered as SRMs. Treating all these SRMs aggressively would lead 
to overtreatment as approximately 20-30% of them are of benign origin (147). 
Most SRMs are diagnosed in the elderly and co-morbid population, making 
postponing the treatment a possible option. Active surveillance is a treatment 
plan for monitoring patients’ condition but giving treatment only if the 
surveilled condition deteriorates. To be included in active surveillance, 
patients have to be sufficiently fit to endure the operative or other active 
treatment.  
The success story of active surveillance of prostatic grade group 1 prostate 
cancer has prompted the interest in surveilling low-stage RCC patients. Both 
cancers are local, slowly growing tumours which are more prevalent in the 
elderly. But distinct features do differ. In active surveillance of SRMs, patients 
are monitored by serial abdominal imaging. Information on histology, grade 
and pathologic stage might be missing as renal biopsy is not mandatory before 
designating patients with SRMs for active surveillance. No serum test, such as 
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S-PSA for prostate cancer, is available for follow-up. Added to this, 
intervention for prostate cancer causes more functional consequences while 
RN or PN is considered having only a minimal effect on quality of life (QOL) 
(148). However, it has been affirmed that preserving nephrons by PN leads to 
better QOL (149) (150). This might suggest that, by choosing not to operate, 
i.e. ‘choosing the ultimate nephron sparing treatment’, might have a beneficial 
influence on certain aspects of QOL. Additionally, no adverse changes in 
mental health were noted when comparing active surveillance to operative 
surgery, according to one multicentre study (151). 
Despite fervent discussions, no agreed-on instructions as to when to move 
from active surveillance to active treatment exist. Arbitrary values of SRM 
diameter growing larger than 4 cm and growing faster than 0.5 cm/year have 
been used (152, 153). Recent results of the multi-institutional Delayed 
Intervention and Surveillance for Small Renal Masses (DISSRM) registry 
affirmed that active surveillance, when tumour diameter is less than 4 cm, was 
not predictive for cancer-specific or OS during a 5-year follow-up time (152).  
However, a meta-analysis by Smaldone et al. determined that almost half 
of the actively surveilled patients (45.4%) ended up having delayed 
intervention at a mean of 30.5 months (range 6-143 months, SD 21.8 months), 
mainly due to patients’ wishes (57.2%), but also as a result of tumour growth 
(35.7%) (154). Of the SRMs actively surveilled, 2% metastasised at a mean of 
40.2 months (154).  
Currently, according to EAU guidelines, following young and healthy 
patients with active surveillance protocol is against recommendations.  
2.5.2 OPERATIVE TREATMENT OF RCC 
Over a century, operative removal of local and locally advanced renal tumour 
has been the treatment of choice. In 1876, Carl Johan Langenbuch performed 
the first successful nephrectomy on a human patient because of a malignant 
tumour. It was not long after this that Spencer Wells in 1884 and Vincenz 
Cerny in 1887 published the first PN results. Although active surveillance has 
been introduced and focal therapies exist, surgery is still the first-line 
treatment for local tumours. 
RN entails the removal of the entire kidney and surrounding perinephric 
fat. PN is recommended for T1 tumours and is an option for larger tumours if 
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technically feasible (155, 156). The indication and possibly gained benefit from 
lymphadenectomy is still controversial. In a recent systematic review by Bindi, 
lymphadenactomy was found not to increase survival either in M0 or M1 RCC 
(157), but contributing studies were sparse and contained risk of bias as only 
one randomised controlled trial was investigated (158). However, when 
adverse clinical features exist, extended lymphadenectomy should be 
considered according to EAU guidelines (13) as a knowledge gap of possible 
survival benefit for subgroups of high-risk M0 RCC still exists. 
The actual procedures (RN or PN) can be performed as conventional open 
procedures or mini-invasive ones using laparoscopic technology with or 
without the 3D technique, robotic assistance or the more rarely used hand 
assistance. Significant debate and research have been ongoing about the best 
practice, previously about the RN vs PN and more recently about the open or 
mini-invasive approaches.  
As was made evident in a randomised, multicentre study by van Poppel et 
al., both PN and RN provide excellent and equal results in terms of oncological 
safety (156). PN, compared with RN, is superior when it comes to renal 
function and QOL after the operation, but similar to CSS and recurrence-free 
survival (RFS), although the OS question remains unanswered (13). Since 
oncologic results are pointed out to be similar, and RN deteriorates kidney 
function more, PN is the first-line treatment for all T1 tumours if no 
contraindications exist (13). In 2015, in all Nordic countries, 55% of all kidney 
tumour treatments were RNs and only 37% PNs (14). 
In comparing mini-invasive with open RN, researchers found no differences 
in CSS, OS or RFS (159, 160). The length of hospital stay, blood loss during 
operation and requirements for anaesthetics were lower for laparoscopic RN 
patients (160). In experienced centres, conventional laparoscopic and robot-
assisted PN yielded similar results to open PN when looking at OS, RFS and 
severe complications (159, 161). Blood loss was lower in mini-invasive PN (161) 
(159). Operation time and warm ischaemia time were longer in laparoscopic PN 
but not in robot-assisted PN compared with open PN (159, 161, 162). Results 
concerning glomerular filtration rate (GFR) decline were somewhat 
contradictory: at least no long-term difference in GFR decline was reported (163, 
164). However, the conventional laparoscopic PN is a challenging procedure and 
comes with a long surgical learning curve. Robot-assisted PN, with articulated 
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wrist instrument motion, has lessened these technical challenges, reduced the 
learning curve and reduced the use on laparoscopic PN (165, 166). Robot-
assisted PN must still be regarded as a demanding procedure. As shown by 
Larcher et al., the learning curve for robot-assisted PN, with respect to 
complications, appears to be endless, without reaching a plateau even after 300 
cases (167). Also, amongst hospital regions, there is assumedly a marked 
variance in the use of mini-invasive techniques, as the choice is dependent of 
financial resources, patient volume and experience of surgeons. 
2.5.3 RENAL CARCINOMA WITH TUMOUR THROMBUS 
Tumour thrombus (TT) reaching the vena cava inferior is a considerable 
adverse prognostic factor for RCC. At the time of diagnosis, up to 10% of RCC 
patients have venous extension added to the primary tumour (168). 
For treating RCC with TT, nephrectomy, combined with thrombectomy, is 
considered the only curative option and sizable surgical resections are accepted 
for curative intention. Evidence to support this is based only on case series with 
limited sample sizes, often with a single-centre design and inhomogeneous 
population (169-171). Results concerning the prognostic significance of the TT 
level have been somewhat controversial as some studies have found the level 
of TT as an independent prognostic factor (172, 173), while some have not (174, 
175). In the presence of non-metastatic disease, surgical removal of the tumour 
and TT are strongly recommended (13), while systemic treatment has been 
reserved for metastatic disease only.  
In a recent retrospective series by Field et al., patients with locally-
advanced or metastatic RCC with TT had improved CSS and reduction in 
tumour and thrombus size after receiving neoadjuvant sunitinib (176). Older 
studies, with smaller patient populations and with a selection of targeted 
therapy offered, have had contrasting results (177, 178), however. More studies 
are needed to confirm if patients who are not able to undergo up-front surgical 
treatment could benefit from neoadjuvant sunitinib prior to surgery. 
Compared with that of localised disease, long-term survival of TT patients 
remains poor (169-171). Survival has been outstandingly poor for patients with 
lymph node metastases. Isolated lymph node disease seemed to predict shorter 
survival (CSS) than single distant metastasis in a large multicentre database 
study by Tilki (170), with the 5-year CSS estimates for lymph node positive 
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disease and single distant metastases being 17.3 (95% CI [9.3–27.4]) and 
36.8% (95% CI [27.0–46.5]), respectively. Patients with TT and tumours with 
papillary histology seemed to be associated with significantly worse outcomes 
as 5-year estimates for pRCC and ccRCC were 36.8% (95% CI [27.0–46.5]) and 
54.8% (95% CI [51.8–57.8]), respectively (172). 
Being major surgery, the surgery of RCC with TT is prone to complications. 
According to a large study by Tilki et al., the overall 30-day postoperative 
complication rate was 34%, and the major complication rate (Clavien 3-5) was 
13% (169). 
2.5.4 ABLATIVE THERAPIES 
Ablation techniques have not gained wide popularity in Finland nor in Nordic 
Countries as initial treatment for kidney tumours (5% and 8%, respectively) 
(14). Ablation therapy options are cryoablation and radiofrequency ablation, 
done percutaneously or laparoscopically. High-quality data to prove oncologic 
outcome or morbidity of ablative therapies is lacking (13). Population-based 
study results about oncologic safety are mixed, but no study has proven 
ablative therapies to be superior to PN (179, 180). A recent meta-analysis found 
that lower morbidity rates and lower GFR reduction favour ablative therapies, 
while CSS and OS do favour PN, and local recurrences and appearances of 
metastasis do not differ between the two treatments (181). Ablative therapies 
are recommended for old and fragile patients as an alternative to PN or active 
surveillance (13). 
2.5.5 ADJUVANT THERAPY 
Surgery is the therapy of choice in non-metastasised RCC. Survival after 
surgery, in locally advanced disease, remains modest, however, since 5-year 
disease-free survival (DFS) for UISS intermediate and high-risk patients has 
been determined to be 64% and 37%, respectively, after nephrectomy (182). 
Also, a number of targeted therapies have been studied for reducing recurrence 
of cancer. 
The findings of the newly published, important trials for Adjuvant 
Sorafenib or Sunitinib for Unfavourable Renal Carcinoma (ASSURE) (183), 
Sunitinib as Adjuvant Treatment for Patients at High Risk of Recurrence of 
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Renal Cell Cancer (S-TRAC) (184), PROTECT (185) and ATLAS (186) are 
mixed. The largest trials to date, ASSURE and PROTECT defined no 
differences between the placebo and treatment arm in DFS or OS, but S-TRAC 
could prove a DFS difference. ASSURE also enrolled patients with T1b and pT2 
disease, whereas S-TRAC only accepted patients with pT3-4 disease. The EAU 
guidelines recommend not to offer adjuvant therapy with sorafenib, pazopanib 
or axitinib (strength of rating: strong) and recommend against sunitinib 
adjuvant therapy in surgically resected high-grade ccRCC (strength of rating: 
weak). Recent meta-analysis did prove a DFS benefit, but without a significant 
improvement in OS, for patients treated with adjuvant TKIs (187). This meta-
analysis comprised all these four studies, also the ATLAS study which was 
missing from the most recent version of guidelines. Patients with greater 
tumour size, T3-T4 tumours and/or nodal metastases did benefit more (187). 
The biological rationale behind the effect of TKIs in an adjuvant setting is 
unknown as is whether or not adjuvant TKI just delays metastases or can if it 
actually prevent recurrence and metastasis. Immune check-point inhibitors 
have been proven to have promising efficacy in metastatic settings, and several 
adjuvant studies on immune check-point inhibitors (PROSPER, IMMotion, 
KEYNOTE and CheckMate) are still recruiting or ongoing, and their results 
scheduled for 2022 to 2024 are eagerly awaited. 
2.6 TREATMENT OF METASTASISED RENAL CELL 
CARCINOMA 
2.6.1 CYTOREDUCTIVE NEPHRECTOMY 
Prior to immunotherapy, nephrectomy for metastatic RCC patients was used 
for the palliation of symptoms (e.g. unendurable pain, bleeding, uncontrolled 
hypertension or hypercalcemia). As well as the option of palliative 
nephrectomy, mRCC patients can undergo cytoreductive nephrectomy, meant 
for reducing of tumour burden, or nephrectomy combined with 
metastasectomy for oligo-metastatic disease aiming to reach a state where 
there is no evidence of disease status.  
During the last decade, the efficacy of CN was proven in two trials by the 
former Southwest Oncology Group (SWOG) (188) and the European 
Organisation for Research and Treatment of Cancer (EORTC), respectively 
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(189). CN followed by interferon α-2b improved survival compared with 
interferon treatment alone (OS 11.1 vs 8.1 months and 17 vs 7 months, 
respectively). Since then, CN has been a routine procedure for patients with a 
large primary tumour, restricted amount of metastases and good performance 
status. However, the use of CN has declined over time. According to recent 
Swedish Cancer Registry, 55% of mRCC patients underwent nephrectomy (2). 
However, contemporary demographic data from the US has indicated that 
distinctly fewer patients, only 30% of those receiving targeted therapy, 
underwent CN (96).  
In the era of targeted therapy, the role and sequence of CN remains an 
unanswered question. Two large prospective and randomised trials, 
CARMENA (11) and EORTC SURTIME (43), tried to answer this question. 
CARMENA compared the efficiency of sunitinib alone with immediate CN 
followed by sunitinib in mRCC patients. Although the trial failed to reach its 
accrual goals, it still had enough power in the intention-to-treat population to 
prove the non-inferiority of sunitinib alone vs CN followed by sunitinib. 
Although OS for sunitinib alone patients was longer (18.4 vs 13.9 months), the 
results of CARMENA cannot prove superiority of sunitinib alone. 
Nevertheless, the CARMENA trial lacks real-world applicability, as operated 
patients were mainly MSKCC intermediate and high-risk patients. The 
proportion of high-risk patients was as high as 43%, although, according to 
earlier evidence, CN for poor-risk patients is discouraged (190). Also, the 
groups did differ as to the proportion of locally advanced tumours (T3 and T4), 
51% and 70.1% for sunitinib alone vs CN-sunitinib group, respectively. 
Bex A et al. studied immediate CN followed by sunitinib versus sunitinib 
followed by deferred CN in a SURTIME trial (43). Results of SURTIME lack 
statistical power to draw any conclusions because of early termination due to 
slow accrual. The main finding of SURTIME was that patients undergoing 
deferred compared with immediate nephrectomy had longer OS, suggesting 
that selecting patients for nephrectomy with a trial phase sunitinib treatment 
might be useful. Because of slow recruiting, the time has almost passed for 
these results from CARMENA and SURTIME to be of any relevance as a newer 
and potentially more efficient option, immunotherapy, has been invented and 
trials with immunotherapy are now ongoing.  
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Based on current evidence, CN does not additionally benefit all mRCC 
patients receiving targeted therapy. Immediate CN still has a role for patients 
with good performance and no need for immediate systemic therapy, patients 
with oligo-metastatic disease when complete removal of metastases can be 
achieved (13) and for intermediate risk patients by MKSCC criteria in the 
absence of progressing disease during systemic therapy. For high-risk patients, 
CN should probably be reserved only for palliation (13). In addition,  patients 
with ccRCC without sarcomatous features and whose tumour burden could be 
reduced markedly (>90% of tumour burden removed) by CN are those who are 
likely to benefit from CN (191) (192). Furthermore, tumour shrinkage of >10% 
after initial oncological treatment and the shrinkage taking place during the 
first 60 days are good prognostic signs and favour CN (193). 
Currently, the combination of the patients’ MKSCC risk score, disease 
progression, amount of metastatic burden and response to systemic therapy 
define those who might benefit from CN. As insightfully stated by Dr Lara et 
al. in JAMA Oncology (194), ‘Ultimately, it may be that the disease rather than 
the physician decides who should undergo surgery.’ 
2.6.2 METASTASECTOMY AND METASTASES-DIRECTED 
THERAPIES 
No evidence of disease status can also be achieved with operative treatment for 
patients with single- or oligo-metastatic resectable disease. More often, 
surgery is only palliative and targeted therapy is needed. Metastasectomy 
remains an option for carefully selected patients although evidence from 
randomised controlled trials is lacking. Most studies comprise only patients 
with ccRCC, so little is known about the benefits for other types of RCC. 
Complete removal of metastases improves survival of mRCC patients 
according to recent systematic reviews (195, 196), although results might be 
affected by patient and tumour-derived factors, since randomised trials are 
lacking. Retrospective works, however, have suggested that both OS and CSS 
are better for complete metastasectomy versus incomplete metastasectomy or 
no metastasectomy at all (195, 197-199). Some small retrospective series 
suggested that survival benefit might be gained even after incomplete resection 
of metastasis compared with no resection patients (197, 198).  
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Metastasectomy does also have a role in palliation and postponing the 
initiation of targeted treatment to avoid associated toxicity (195, 200). To avoid 
the complications of surgery, non-surgical metastases directed-therapies, i.e. 
stereotactic radiotherapy and thermal ablation, have been used to treat 
metastases and symptoms of metastases.  
The most common sites of metastasis in RCC are the lungs (45%), bones 
(30%), lymph nodes (22%), liver (20%), brain (8%) and adrenal glands (8%), 
but any site is practically possible (201). The primary recurrence sites are the 
lungs (54-64%), lymph nodes (22%) and bones (15-20%) (138, 202). Less 
common sites include distant lymph nodes, adrenal glands, local recurrences, 
pancreas, liver and brain. Metastasectomy is the most relevant local treatment 
to all metastatic sites, except brain and possibly bones. Many prognostic 
factors for metastasectomy are presented in Figure 9, including patient-
derived factors, features of cancer and completeness of surgery (195) (203). 
Factors associated with favourable outcomes after metastasectomy include 
good performance status and cancer risk status of good or intermediate risk 
(by MSKCC or Heng risk score), metastasis being metachronous with primary 
tumour, recurrence-free interval being over two years, metastasis being 
solitary or oligo-metastatic, metastasis emerging in a single organ, absence of 
nodal metastasis, clear-cell histology, absence of a sarcomatoid component 
and low-to-moderate Fuhrman grade (199). 
EAU guidelines recommend metastasectomy if complete resection is 
achievable and beneficial prognostic factors exist or for mere palliation (13). 
Other local therapies can be used for palliative purposes; for example, 
stereotactic radiotherapy comes with low toxicity and can significantly 
improve local symptoms caused by brain and bone metastasis (204). 
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Figure 9 Prognostic factors for surgery of RCC metastasis. Data from publications 
Dabestani et al. Local treatments for metastases of renal cell carcinoma: a 
systematic review. Lancet Oncol. 2014 Nov; 15(12):e549-61 and Dabestani S. et 
al. Metastasis therapies for renal cancer. Curr Opin Urol. 2016 Nov; 26(6):566-
72. 
As stated earlier, MKSCC risk categories determine patients suitable for CN 
but no nomogram is agreed upon for choosing patients for metastasectomy. 
Tosco et al. proposed a clinical tool that could be helpful when deciding 
amongst treatment options for mRCC patients by assigning metastatic patients 
to different risk categories by their prognosis (205). The LU prognostic group 
system divides patients into four different prognostic groups (Figure 10). The 
system provides a useful clinical tool, but it needs external validation before it 
can be adopted to practise. 
Favourable prognostic features for  
metastasectomy 
Patient factors 
 
• Good performance 
status (ECOG 0-1)   
• MKSCC or Heng 
score favourable 
or intermediate 
risk  
Disease related factors 
 
• Solitary metastasis  
• Single organ site  
• Absense of nodal 
metastases 
• Disease-free interval from 
nephrectomy >2 years 
• Metachronous metastases 
• Absence of progression to 
treatment  
• Metastasis free status 
achievable (=complete 
metastasectomy)  
Tumour-related 
factors 
 
• ISUP group 
(Fuhrman grade)  
• No sarcomatoid 
features 
• Clear-cell subtype 
Favourable sites 
 
• Lung 
• Pancreas 
• Liver 
• Thyroid 
• Adrenal glands 
Organ sites for 
metastases 
Sites with poor 
Prognosis 
 
• Brain 
• Bone 
• Lymph nodes 
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Figure 10 Leuven-Udine prognostic groups. 
There are some ongoing prospective studies. One is the RESORT trial, 
which compares complete metastasectomy and targeted therapy vs 
metastasectomy and best supportive care until disease recurrence. An ongoing 
randomised controlled trial by National Cancer Institute (NCT01575548) 
compares metastasectomy and pazopanib vs metastasectomy and placebo. 
However, currently, complete metastasectomy remains the only possible cure 
for limited metastatic disease in the presence of favourable prognostic factors. 
It may also offer significantly longer CSS and OS, defers time to systematic 
treatment and relieves symptoms. 
2.6.3 SYSTEMIC THERAPY 
The first medications for RCC were immunotherapy preparations interferon-α 
(IFN-α) and interleukin-2 (IL-2). But, since the implementation of targeted 
therapy, the use of IFN- α and IL-2 has become limited. 
Targeted therapies are intended to inhibit the critical signalling pathways 
of RCC. Targeted therapy comprises VEGF antibodies, tyrosine kinase and 
multikinase inhibitors and mTOR inhibitors (206). Sunitinib and pazopanib, 
both TKIs, are the first-line treatment options for treatment-naïve mRCC of 
IMDC favourable risk (13). Targeted therapies have proven survival benefits 
compared with IFN-α, but durable remissions are rare (206) as cancer finally 
develops resistance to these medications. With sunitinib or pazopanib as a 
first-line treatment, the median PFS is from 8 to 11 months for all patients 
(207, 208). A more novel multi-kinase inhibitor, cabozantinib, is 
recommended as a first-line treatment for treatment-naïve mRCC of IMDC 
intermediate or poor risk (13) 
By inhibiting immune cells of the host through overexpression of immune 
checkpoint molecules, cancer cells escape the immune reaction (209). By 
 
LU prognostic groups 
A:  0-1 risk factors 
B:  2 risk factors 
C:  3 risk factors 
D:  4-5 risk factors 
Risk factors 
• T-stage >3 
• Fuhrman grade >3 
• Disease free interval ≤12 months 
• Nonpulmonary metastases 
• Multiple mestatic sites 
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weakening the negative regulation of immune defence, the immune reactions 
of the host are boosted to fight intruding cells (210). Cytotoxic T-lymphocyte 
associated antigen 4 (CTLA-4) is a receptor, which turns off the activation of T 
cells to prevent excessive reaction. A more physiological and less expensive way 
is to unwind the downregulation of readily activated T cells by selectively 
blocking the interaction between programmed death 1 (PD1) receptor and 
programmed death-ligand 1 (PD-L1) (210).  
The phase III trial CheckMate 214 (NCT 02231749) proved that a 
combination of ipilimumab (CTLA-4 inhibitor) and nivolumab (a PD-1 
immune checkpoint inhibitor) in treatment-naïve advanced or mRCC patients 
to be superior to sunitinib in terms of response rate and OS but also in health-
related QOL assessment (211). Therefore, the most recent recommendation by 
EAU is to use ipilimumab plus nivolumab as a treatment for IMDC 
intermediate and poor-risk previously untreated patients (13). However, 
widely removing the downregulation of the immune system is not innocuous: 
even life-threatening autoimmune reactions may happen, and more selective 
immunological medication is highly anticipated. 
2.6.4 PRECISION MEDICINE – THE WAY OF THE FUTURE 
Over its history, cancer has been perceived as a disease of an organ, and 
oncologic treatment has been chosen for the organ involved, e.g. TKIs for RCC. 
In addition, treatments have been traditionally designed for the ‘average 
patient’. Consequently, treatments have been effective for some but not for all, 
and the effect of the treatment has been tested with a trial period for each 
cancer patient. By contrast, precision medicine, e.g. personalised medicine, is    
treatment taking into consideration genetics as well as molecular and cellular 
features of the tumour (212) 
RCC is, however, not a single entity, but includes various subtypes of 
tumours. Also, intra- and inter-tumour heterogeneity is huge, being a major 
obstacle to selecting individual, and effective, treatment for mRCC. As 
demonstrated by Saaed et al., even cells form different tumour regions and 
respond differently to cancer medication (213). In clinical research, the bulk 
tumour has  already been handled with surgery or one drug, and tumour 
subclones simultaneously with some other drug (214). Some promising tissue-
based predictive biomarker studies for mRCC exist, but to validate the results, 
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larger studies are needed. Due to the heterogeneity of the index tumour and 
metastases, precision medicine will be essentially dependent on tissue samples 
for now until more accessible biomarkers emerge. 
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3 AIMS OF THE STUDY 
Currently, the prognosis of an individual patient with a renal tumour still 
cannot be accurately predicted due to the heterogenous behaviour of tumours. 
The ongoing question concerning which patients should be designated for an 
operation is more relevant than ever when tumours are ranging from tiny, 
indolent tumours to life-threatening metastasised disease. Additionally, 
patients are getting older and more vulnerable. Thus, the low number of 
complications, good surgical quality and reasonably accurate estimate of life 
expectancy are of utmost importance when deciding on the treatment.  
The aims of this study were to evaluate the contemporary landscape and 
quality of surgical treatment in the Helsinki metropolitan area and identify 
prognostic factors of RCC. 
The specific aims were as follows: 
1) To evaluate changes in the clinical picture and treatment of RCC (I) 
2)  To evaluate the efficacy of surgery in RCC patients with TT (II) 
3) To ensure that anatomical factors and models predict the type of 
nephrectomy, and that they have impact on recurrence (III) 
4) To evaluate the outcome of metastasectomy of RCC patients and assess 
the performance of the LU prognostic model (IV) 
5) To appraise the value of s-TATI as a prognostic marker (IV). 
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4 PATIENTS AND METHODS 
4.1 STUDY COHORTS AND TIMELINES 
The patient cohorts are described in detail in the original publications (I-V). 
All patients studied had the clinical condition of RCC (II-V) or were suspected 
to have RCC (I). All patients in studies II-V underwent nephrectomy at the 
Helsinki University Hospital (HUH). 
We searched the consecutive patients for each study from either the 
Helsinki University Kidney Tumour Database or Helsinki University Hospital 
urological and oncological outpatient registries. Statistics Finland provided the 
death certificates, but all other information was gathered from patient 
registries. 
Tumours were histologically classified according to either WHO 2004 
classification (II and III) (46) or WHO/ISUP 2013 classification (studies I, IV 
and V) (88) and staging of tumours according to TNM 2009 classification (58). 
For studies II and IV, we recorded postoperative complications occurring in 
the first 30 days after operation and graded them according to the Clavien-
Dindo classification of surgical complications published by Dindo et al. (215). 
Patient and tumour characteristics of each substudy are presented in Table 6. 
4.1.1 STUDY I 
To describe the whole population with kidney tumours, the outpatient 
registries of urological and oncological departments and the institutional 
kidney tumour register, covering the entire Helsinki and Uusimaa Hospital 
District (HUH) of 1.67 million patients, were searched for ICD10 codes of 
D41.0 and C64.88. The intention was to single out all patients with tumours 
suspected of being RCC from 2006 to 2016. Having a publicly financed 
healthcare system and being the only referral institute for urology in the area, 
these registries comprise nearly all renal tumour patients of the metropolitan 
area of Helsinki, providing a comprehensive data collection on renal tumours 
in a current population. 
We identified 1,719 patients who had either a solid or a cystic mass (Bosniak 
3-4), with a maximum diameter ≥10 mm. We wanted to study the change in 
presentation and treatment patterns, especially the changing proportion of 
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active surveillance. Deciding the right treatment often demands some time, so 
treatments during the first six months after tumour diagnosis were included 
and meticulously collected from oncological and urological patient records. 
Patients received urologic treatment, oncologic treatment or observation due 
to their renal tumours. Not all the tumours being followed up had known 
histology, as is also the case in real life. The timeline of study was divided into 
four time periods, 2006-2008, 2009-2011, 2012-2014 and 2015-2016, to 
obtain better a perception of changes over time. 
Table 6. Clinicopathological data of substudies. 
Clinicopathological data of substudies 
      
 Study I Study II Study III Study IV Study V 
      
Patients (n) 1,719 142 915 97 132 
Male (%) 988 (57) 95 (67) 499 (54) 57 (59) 62 (47) 
Age (years), mean (SD) 66 (13) 65 (14) 63.4 (13) 64 (4) 64 (18) 
      
When conducted (years) 2006-2016 2006-2014 2006-2014 2006-2017 2005-2010 
      
Nephrectomies (n, %) 1107 (64) 142 (100) 915 (100) 97 (100) 132 (100) 
PN/RN 482/625 0/142 388/527 7/93 NA 
      
Malignant tumours (n, 
%) 
1,103 (62) 142 (100) 764 (84) 97 (100) 132 (100) 
ccRCC 803 (73) 129 (91) 546 (75) 86 (89) 114 (86) 
pRCC 210 (19) 10 (7) 114 (16) 8 (8) 15 (11) 
chroRCC 62 (6) 1 (0.7) 53 (7) 0 (0) 1 (0.8) 
Fuhrman grading      
Grade 1-2  38 (27) 510 (71) 19 (20) 64 (48) 
Grade 3-4  104 (73) 199 (28) 78 (80) 63 (48) 
      
TNM grading      
T-stage 1-2 710 (64%) 0 584 (76%) 24 (25) 58 (44) 
T-stage 3-4 393 (36%) 142 (100) 180 (24%) 73 (75) 74 (56) 
Median diameter of 
tumour (mm), mean (SD) 
55.5 (36.4) 103  (36) 53.6 (33.7) 80 (15.3) N.A. 
N=0  118 (83) 728 (99.6) N.A. * 118 (89) 
N=1  24 (817) 3 (0.4) N.A. * 14 (11) 
M=0  88 (62) 723 (99) 0 107 (81) 
M=1  54 (38) 8 (1) 97 (100) 25 (19) 
N.A.= Information not available. *Only information of patients with removed metastatic lymph 
nodes (n=4) was available for metastatic patients. This was not included in the table because 
it is not comparable with other studies. As in other studies, lymph nodes, suspicious for 
malignancy in preoperative imaging, were also included. SD =standard deviation, PN = 
partial nephrectomy, RN= radical nephrectomy, ccRCC = clear cell renal cell carcinoma, 
pRCC = papillary RCC, chroRCC = chromophopic RCC. 
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4.1.2  STUDY II 
Study II comprised 142 patients with TT treated with nephrectomy from 2006 
to 2014 in Helsinki University Hospital. Patients were identified from the 
Helsinki University Kidney Tumour Register. The majority were inhabitants of 
Helsinki University Hospital district, but some had been referred from other 
hospital districts. Follow-up details were collected from different hospitals and 
healthcare centres around Finland. Treatment intention, radical or 
cytoreductive, was not an exclusion criterion. The diagnosis of RCC and the 
level of TT were detected originally from the CT scans taken preoperatively and 
were further defined after the analysis of pathological specimen. The majority 
of the patients (95%) underwent whole-body CT and 4% underwent chest X-
ray and abdominal CT/MRI.  
Mainly studies with small patient populations were conducted during the 
era of targeted therapy, and the prognostic importance of the TT level was 
debatable at the time of this study. The study tested the prognostic importance 
of TT level after surgical management. This required reclassification of TT level 
according the current TNM classification (2009) and careful recording of 
adjuvant oncologic treatments. The proportion of patients with 
supradiaphragmatic TT was modest in our study (n=9, 6%). Figure 11 presents 
a rare case of supradiaphragmatic TT. 
 
       
a)      b)                c) 
Figure 11 Rare case of patient with tumour thrombus (TT) extending to the right atrium. 
Less than 1% of TTs reach the cardiac chambers. a) Preoperative CT: Necrotic 
6 cm-sized primary tumour in right kidney was found when imaging patient due 
to recent pulmonary embolia. b) Preoperative CT of the TT. However, the 
cephalic level of the TT was best visualised with cardiac echo. c) TT broken into 
two pieces after resection, and kidney removed en bloc. Cardiac extension 
marked with an arrow. Cardiac bypass and cell-saving technique for blood were 
used. Only a resection of inferior vena cava was needed, as the TT was non-
attached from its cephalic extension. CT images are received from HUS urology 
clinic patient archives’. Photo of TT was taken by the author. 
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4.1.3 STUDY III 
Study III evaluated the performance of most fundamental tumour 
characteristics, tumour diameter and parenchymal invasion depth, compared 
with more compound classifications, such as PADUA classification and RTII, 
in predicting the type of nephrectomy performed. Nephrectomy types 
compared were PN (n=388, 42%) and RN (n=527, 58%). Patients underwent 
operations at Helsinki University Hospital from 1.1.2006 to 31.12.2014 for 
tumours suspicious for malignancy. The information was retrieved from 
Helsinki University Kidney Tumour Register. 
Twenty-six consultant urologists performed or assisted in these 1,284 
operations. The type of nephrectomy was ultimately decided by the primary 
surgeon based on CT or MRI imaging of the tumour and patient-derived 
factors. No anatomic classifications were used as a decision aid at the time of 
the study. For this study, tumour maximal diameter, the depth of parenchymal 
invasion, PADUA classification and RTII were assessed by one urologist only 
according to published methods (62, 68). 
4.1.4 STUDY IV 
Study IV was conducted to assess the safety and efficacy of metastasectomy for 
RCC patients and to test the performance of the previously published LU 
prognostic group model. The Helsinki University Kidney Tumour Register was 
searched for patients with surgically treated metastases of RCC, and it 
provided 97 patients with sporadic metastatic RCC treated from 2006 to 2017. 
All patients included in the study also ultimately underwent surgical treatment 
for the primary tumour. Medical oncologists planned oncological treatments 
according to prevailing practise when no curable surgical treatment existed. 
After nephrectomy and metastasectomy, patients were followed up with 
imaging, laboratory tests and physical examinations according to risk of 
recurrence. The LU prognostic groups comprised patients with 0 to 5 risk 
factors, and the patients were divided to groups according the original 
publication by Tosco et al. (205) (Figure 10). 
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4.1.5 STUDY V 
Study V looked into the value of the serum marker TATI in predicting outcomes 
after nephrectomy. Patients (n=173) who had undergone either PN or RN at 
Helsinki University Hospital from 2005-2010 for any kind of renal tumour 
were included in this study. Patients with benign histology or non-RCC cancer 
as well as patients with severely reduced renal function were excluded from 
this study (n=41). No patient had acute infection or pancreatitis at the time of 
serum sample measurement. We used preoperative CT of the thorax, abdomen 
and pelvis to determine the metastatic status, but the status was updated if 
positive lymph nodes were seen in pathological examination.  
Serum samples were taken preoperatively at a median of 1.0 day (range 0-
50 days) prior to the operation and a minimum of 3 weeks after nephrectomy 
(median of 52 days, range 25-176 days), to avoid the effect of inflammatory 
response caused by surgery. Serum samples were stored at -20oC before the 
assay. S-TATI was determined by time-resolved immunofluorometry assay 
(TR-IFMA) according to methods previously described.  
4.2 STATISTICAL ANALYSIS 
All statistical analyses were performed with IBM SPSS Statistics versions 22-
24 (IBM, Armonk, NY, USA). Statistical significance was set at P<0.05 in two 
sided-tests.  
In studies I and III, the tests used to assess comparisons amongst 
clinicopathological factors were done with Student t-test and chi-squared test 
for continuous and categorical variables, respectively. In study V, associations 
between S-TATI and clinical variables were calculated using Spearman’s rho, 
Mann-Whitney U test and Kruskall-Wallis test, when appropriate. The 
Wilcoxon signed-rank test was used to analyse differences of medians of pre- 
and postoperative S-TATI measurements. 
In publications II, IV and V, the survival times (OS, CSS and RFS) were 
defined as the time from nephrectomy to death from any cause, to death from 
RCC or to first recurrence, respectively. In study IV, the OS and the RFS were 
calculated from the first surgery for metastases. The Kaplan-Meier estimate 
was used to analyse the median survival times with 95% CIs for all CSS, RFS 
and OS, and statistical significance amongst groups was analysed using a log-
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rank test. Effects of clinicopathological data and other factors studied were 
assessed using uni- and multivariate Cox proportional hazard models. These 
results are expressed as odds ratios (ORs) with 95% CI. 
In study III, we calculated the receiver operating characteristic (ROC) 
curves with areas under the curve (AUCs) to compare the effect of anatomical 
parameters in predicting the type of nephrectomy. We performed 
multivariable regression analyses for nephrectomy type using a backward 
stepwise likelihood ratio test. The anatomic variables correlated strongly. 
Therefore, we tested them separately and combined them with a constant 
group of independent non-anatomic cofactors (hypertension, age and year of 
surgery) aiming to recognise the real-life effect of a single anatomic factor. By 
expressing the observed results as a percentage of the expected results, the 
goodness of fit of the models was determined. 
4.3 ETHICS 
All data for studies I-IV were collected retrospectively from Helsinki University 
Kidney Tumour Database and Helsinki University urological and oncological 
patient registries, without requiring informed consent from patients. In study 
V, patients had given informed consent at enrolment before the planned 
nephrectomy. The Ethics Committee of the Helsinki and Uusimaa Hospital 
District approved all studies. 
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5 RESULTS 
5.1 STUDY I 
The study of 1,719 patients with kidney tumours suspected of malignancy 
showed that the field of renal surgery had changed markedly over the 10-year 
span of the study. The number of septuagenarians and older patients increased 
from period I (2006-2008) to period IV (2015-2016; p=0.067) (Figure 12). 
Operated on patients also became more ill and frailer, as the percentage of 
patients with CCI ≥2 and with ECOG ≥2 increased from 33% (period I) to 44% 
(period IV; p=0.019) and 19% (I) to 36% (IV; p<0.001), respectively. Tumours 
were more often incidental (p<0.001), and the percentage of small tumours 
(diameter ≤4 cm) diagnosed increased from 36% (I) to 54% (IV; p<0.001).  
 
Figure 12 Increasing proportions of older and more fragile patients with smaller tumours 
during the study periods I-IV (from 2006-2008 to 2015-2016). Illustration 
previously unpublished by author. 
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As patients got older and more vulnerable with smaller tumours, the 
treatment pattern also changed. The use of observation, including both active 
surveillance and watchful waiting, as forms of urological treatment delivered 
within six months from diagnosis, increased significantly (Table 7). During 
period I, 8% of patients had a needle biopsy taken from the tumour compared 
with 19% in period IV (p<0.001). From period I to period IV, RN decreased 
from 66% to 30% (p>0.001), respectively. The use of CN decreased 
significantly as well from 72% (I) to 54% (IV; p=0.032).  
Table 7. Initial urological treatments (during first six months from diagnoses) for patients 
with small tumours suspected for RCC. a = Chi-square test between radical and 
partial nephrectomy. b = Chi-square test between active urological treatment and 
observation methods. RN=radical nephrectomy, PN= partial nephrectomy, RFA= 
radiofrequency ablation.   
Variable All 2006-2008 2009-2011 2012-2014 2015-2016 p-value 
n=1,457  
n (%) 
n=265 
n (%) 
n=397 
n (%) 
n=462 
n (%) 
n=333 
n (%) 
 
Initial urological treatment 
RN 625 (42.9)  176 (66.4) 194 (48.9) 156 (33.8) 99 (29.7) <0.001a 
PN 482 (33.1) 65 (24.5) 123 (31.0) 166 (35.9) 128 (38.4)  
RFA 5 1 3 0 1  
Active 
surveillance 
260 (17.8) 22 (8.3) 59 (14.9) 98 (21.2) 81 (24.3) <0.001b 
Unfit for 
treatment 
76 (5.2)  1 (0.4) 16 (4.0) 38 (8.2) 21 (6.3)  
Refusing to 
be treated      
9 0 2 4   
Table modified from one published in Urologia Internationalis 102(4),390-398, 2019, Erkkilä 
et al., ‘Evolving Clinical Picture of Renal Cell Carcinoma: A Population-Based Study from 
Helsinki’ by permission from S. Karger Publishers Ltd. 
5.2 STUDY II 
Despite the evolved treatment of metastatic RCC, the long-term survival of 
patients with RCC and TT has remained modest. In our study, the 5-year CSS 
rate for non-metastatic patients was 59% and 38% for patients with distal 
metastases. The median CSS for patients with lymph node involvement was 
particularly poor, 10 months, whereas it was 63 months for patients with n0 
disease (p<.01) (Figure 13). 
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Figure 13 CSS by metastatic state and lymph node involvement. Figures reprinted by 
permission of Taylor & Francis Group. Scandinavian Journal of Urology 2016, 
50(5), 380-386, Tornberg et al., ‘Outcome of surgery for patients with renal cell 
carcinoma and tumour thrombus in the era of modern targeted therapy’. 
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The level of TT failed to be a significant prognostic predictor of survival in 
our study – the mean (median) CSS rates for renal vein, subdiaphragmatic 
vena cava and supradiaphragmatic vena cava were 68 (79) months, 56 (50) 
months and 43 (not acquired) months, respectively (p=.42).  
     
Figure 14 Systemic therapy delivered first- and second-line. Illustration previously 
unpublished by author. 
The majority of patients (62%, 88/142) were operated on with radical 
intention and 38% (54/142) with cytoreductive intention. During the follow-
up time, 73 patients (51%) received postoperative targeted therapy (Figure 14).  
Major complications (Clavien-Dindo classification 3-5) were rare (Table 8). 
Two postoperative deaths occurred with the 30-day mortality being 1%. The 
overall complication rate was 34%. 
5.3 STUDY III 
In study III, the proportion of PN increased significantly, from 25% in 2006-
2008 to 50% in 2012-2014 (p<0.001) for all tumours. In the last study period 
(2012-2014), patients with T1a tumour underwent PN in 87% of cases, which 
differed significantly from the first period (59%; p<0.001). In multivariable 
regression, younger age, absence of hypertension, later year of surgery, lower 
tumour invasion, smaller diameter and lower PADUA score were significantly 
associated with performance of PN. 
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Table 8. Thirty-day complication rate according to Clavien-Dindo classification for 
complications for nephrectomy with tumour thrombectomy.                                  
Clavien-Dindo grade All patients TT reaching 
renal vein 
TT reaching 
subdiaphragmatic 
vena cava 
TT reaching 
supradiaphragmatic 
vena cava 
 n (%) n (%) n (%) n (%) 
 142 (100%) 81 (100%) 52 (100%) 9 (100%) 
No  complications 94 (66.2) 61 (75.3) 29 (55.8) 4 (44.4) 
1 1 (0.7) 0 (0) 0 (0) 1 (11.1) 
2 34 (23.9) 14 (17.3) 17 (32.7) 3 (33.3) 
3a 1 (0.7) 0 (0) 1 (1.9) 0 (0) 
3b 6 (4.2) 2 (2.5) 4 (7.7) 0 (0) 
4a 4 (2.8) 2 (2.5) 1 (1.9) 1 (11.1) 
4b 0 (0) 0 (0) 0 (0) 0 (0) 
5 2 (1.4) 2 (2.5) 0 (0) 0 (0) 
Total number of 
complications 
48 (33.8) 20 (24.7) 23 (44.2) 5 (55.5) 
Number of major 
complications 
(Clavien-Dindo 3-5)  
12 (8.5) 6 (7.4) 6 (11.5) 1 (11.1) 
Table modified from one published in the Scandinavian Journal of Urology 50(5),380-386, 2016, 
Tornberg et al., ‘Outcome of surgery for patients with renal cell carcinoma and tumour thrombus 
in the era of modern targeted therapy’ with the permission of the Taylor & Francis Group.  
When comparing the anatomical scores, in ROC/AUC analysis, the invasion 
(AUC 0.92, 95% CI [0.90-0.94]), as well as diameter and RTII, performed 
better at predicting the nephrectomy than PADUA (AUC 0.88, 95% CI [0.85-
0.90]). In the multivariable regression model, adding one anatomic factor to 
the consistent group of non-anatomic factors was useful, but adding more 
anatomic factors did not improve the performance significantly. The best 
model with one anatomic factor was reached with invasion (Table 9). 
Table 9. Comparison of different multivariable regression models for best combination 
predicting performance of PN. RTII: Renal tumour invasion index; PADUA: 
Preoperative Aspects and Dimensions Used for an Anatomical (PADUA) 
classification score.             
Modality Anatomical factors included in 
the model 
Percentage 
classified 
correctly (%) 
Non-anatomic factors (age, 
hypertension, and year of surgery) 
None 63.0 
Non-anatomic factors combined with 
one anatomic factor 
Invasion                                                                 
RTII                                                        
Diameter                                                    
PADUA 
85.6                              
84.4                                    
84.0                                         
81.8                                    
Non-anatomic factors combined with 
two anatomic factors 
Invasion + Diameter                              
Invasion+RTII                                 
Invasion+PADUA                                
86.0                                      
86.0                                       
85.6            
Non-anatomic factors combined with 
three anatomic factors 
Invasion+Diameter+RTII                           
Invasion+Diameter+PADUA                        
86.7                                 
86.3
Non-anatomic factors combined with 
four anatomic factors 
Invasion+Diameter+RTII+PADUA                            86.4
Table modified from one published in Scandinavian Journal of Surgery 2018 Mar; 107(1):54-
61. Tornberg et al. ‘Renal Tumor Invasion Depth and Diameter are the Two Most Accurate 
Anatomical Features Regarding the Choice of Radical Versus Partial Nephrectomy’. 
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Tumour stage, i.e. tumour size in local tumours, is the most important 
prognostic factor for RCC. However, no studies concerning invasion as a 
predictor of recurrence have been published to the best of my knowledge. 
Using the patient data of study II on patients with non-metastasised malignant 
tumours (N0M0) (n=731) who had undergone nephrectomy with radical 
intention, we investigated to determine if invasion could predict recurrence 
and survival. As expected, T-stage, dichotomised to T1 and T2, predicted 
recurrence in Kaplan-Meier analysis as did invasion (dichotomised in two 
groups, invasion being either <25 mm or ≥25 mm) (p<0.005) (unpublished 
finding by the author) (Figure 15). These results could be expected as these 
measurements are strongly correlated. Invasion, diameter and Fuhrman grade 
were statistically significant predictors of recurrence in univariate analysis, 
while histology was not. Also, invasion, Fuhrman grade and diameter all 
remained statistically significant in multivariable analysis predicting 
recurrence (unpublished finding by the author) (Table 10).  
For predicting CSS or OS, invasion excelled in univariate analysis, but the 
effect was lost in multivariate analysis when compared with diameter or T-
stage (dichotomised to T1a/T1b or T1/T2) and Fuhrman grade. 
Table 10. Results of univariate and multivariate analysis of recurrence of tumours with 
NoMo status at the time of operation. 
   Univariate analysis Multivariate analysis 
  Patients 
(n) 
HR 95% CI p HR 95% CI p 
Invasion 
As a continuous 
variable 
680 1.03 1.02-1.04 <0.001 1.013 1.00-1.02 0.005 
Diameter 
As a continuous 
variable 
680 1.01 1.01-1.01 <0.001 1.007 1.00-1.01 <0.001 
Fuhrman grade 
 1 97 1   1   
 2 402 2.10 0.64-6.94 0.22 2.64 0.64-10.79 0.18 
 3 166 10.07 3.12-32.47 <0.001 9.36 2.34-37.44 0.002 
 4 19 31.72 9.02-111.49 <0.001 30.39 7.20-128.44 <0.001 
Histology 
 ccRCC 537 1  0.04 1  0.02 
 pRCC 112 0.42 0.19-0.91 0.03 0.52 0.24-1.13 0.10 
 chroRCC 52 0.43 0.14-1.37 0.16 0.24 007-0.78 0.02 
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Figure 15 Recurrence by T-stage, divided into T1a and T1b, and invasion with the cut-off 
of 25 mm. Illustration previously unpublished by author. 
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5.4 STUDY IV 
The 97 patients underwent 90 nephrectomies, 7 PNs and 128 operations for 
metastases. Only a minority (15%) of metastasectomies were performed 
simultaneously with the operation on the primary tumour. Most of patients 
(66/97) underwent one metastasectomy operation, and two operations and 
three or more operations were done to 24 and 7 patients, respectively. The 
majority of patients who had undergone metastasectomy had synchronous 
metastases (62%), and in 37% of patients the metastases emerged after 
radically intended nephrectomy. The thirty-day complication rate for overall 
major complications was 11%, and the 30-day mortality rate was 1 % (Table 11). 
Table 11. Thirty-day complications of metastasectomies with the Clavien-Dindo 
classification. 
Clavien-Dindo Grade All patients Initial 
metastasectomy 
Complications in the 
operations after the first 
round of metastasectomy 
 N (%) N (%) N (%) 
    
No complications 84 (63%) 61 (63%) 23 (74%) 
1 11 (9%) 9 (9%) 2 (7%) 
2 19 (15%) 14 (14%) 5 (16%) 
3a 4 (3%) 4 (4%) 0  
3b 2 (2%) 2 (2%) 0  
4a 6 (5%) 6 (6%) 0  
4b 1 (1%) 1 (1%) 0  
5 1 (1%) 0  1 (3%) 
Total number of 
complications 
44 (34%) 36 (37%) 8 (26%) 
Number of major 
complications 
(Clavien-Dindo 3-5)  
14 (11%) 13 (13%) 1 (3%) 
Table reprinted by permission of the Taylor & Francis Group. Scandinavian Journal of 
Urology 2018 Oct - Dec;52(5-6):419-426.Tornberg et al., ‘Surgery for metastases of renal 
cell carcinoma: outcome of treatments and preliminary assessment of Leuven-Udine 
prognostic groups in the targeted therapy era’.  
The estimated median OS was 67 months (Interquartile range (IQR) = 30-
130). Patients with complete metastasectomy had significantly better 5-year 
OS compared with those with non-complete metastasectomy, 59% and 45%, 
respectively (p=0.030). Figure 16 shows site-specific survival, median survival 
by sites being 35 (95% CI [16-53]), 77 (58-96), 60 (not available) and 58 (49-
67) months for bone, lung, brain and adrenal metastases, respectively.  
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Figure 16 OS by different sites of surgery for RCC metastases. Illustration previously 
unpublished by author. 
Up to 61% of patients, who had undergone complete initial metastasectomy, 
experienced recurrence and the median RFS after complete metastasectomy 
was 10 months (IQR = 3-37).   
Half of the patients (57%) were on systemic therapy. The estimated median 
time from diagnosis to oncological treatment was shorter (p=0.006) for 
patients with non-complete metastasectomy, 19 (IQR = 1-71) months, but for 
those with complete metastasectomy, at the time of analysis, the median time 
was not achieved. Figure 17 presents the oncologic systemic treatments 
administered in the first- and second-line medication. 
 65 
    
Figure 17 Targeted therapy administered in the first- and second-line for mRCC patients. 
Illustration previously unpublished by author. 
Our study population had more patients with inauspicious prognostic 
markers, e.g. a larger number of patients with synchronous metastases at the 
time of diagnosis (p<0.001), more patients with multiple metastatic sites 
(p<0.001) and worse ECOG scores compared with the patient population in 
the study by Tosco et al. (p=0.003) (Table 2 in original publication). The 
number of patients distributed in LU prognostic groups differed significantly 
between these two studies (p>0.001). In our study, we could not validate the 
performance of LU prognostic groups in predicting CSS. The 5-year CSS for LU 
prognostic groups A, B, C and D were 0%, 74%, 56% and 45%, respectively 
(p=0.42), and no difference was noted amongst groups B-D after exclusion of 
the minuscule group A of 2 patients (p=0.220). 
5.5  STUDY V 
The study’s population of 132 patients was quite heterogenous, as 44% of 
patients had local disease (T1-T2), and 56% had locally advanced disease (T3a-
T4). Of these patients, 11% had lymph node involvements, and 19% had 
metastatic disease. The median preoperative and postoperative concentrations 
of S-TATI for all patients were 13.0 µg/l (IQR = 9.9-19.5) and 18.3 µg/l (IQR = 
13.6-24.3), respectively. Figure 18 shows the distribution of S-TATI in the cases 
of malignant and benign disease.  
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Figure 18 Distribution of S-TATI in malignant and benign diseases. Median preoperative S-
TATI for malignant disease being 13.0 µg/l (IQR 10.0-20.0) and for benign 
disease 11.4 µg/l (IQR 8.7-14.1). Illustration previously unpublished by author. 
Preoperative S-TATI measurements were significantly associated with 
several known prognostic markers for RCC, including T-stage (p=.006), lymph 
node involvement (p=.04), metastatic state (p=.94) and preoperative CRP level 
(p=.01). It was also associated with chronic kidney disease (CKD) grade 
(p<.001). The only significant association with postoperative S-TATI was 
noted between CKD grade and S-TATI (p<.001).   
Postoperative S-TATI measurements were associated with both OS and CSS 
in the univariate Cox proportional hazards model (Table 2 in original 
publication). In multivariate analysis for OS, S-TATI remained statistically 
significant (p=.03) with age (p=.004), lymph node status (p<.001) and M-
stage (p=.003). Additionally, for CSS, S-TATI (p=0.004), T-stage (p=.012), N-
stage (p=.003) and M-stage (p=.001) remained significant (Table 3 in original 
publication) in multivariate analysis. 
The cut-off of 16 µg/l seemed to predict OS and CSS significantly in the 
Kaplan-Meier analysis and univariate Cox proportional hazards model only 
(Figure 19). 
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Figure 19 OS for patients with RCC after surgery according to pre- and postoperative S-
TATI measurements. 
Only 26 patients (26%) had disease recurrence after operations with radical 
intention. Also, we did not determine any association between postoperative 
dichotomous S-TATI with a cut-off of 16 µg/l and an increased risk of 
recurrence (p=.2).  
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6 DISCUSSION 
The marked increase of incidentally found renal tumours has been estimated 
to have reached a plateau or even started to decline, at least in Europe (18). As 
the population ages, a larger proportion of renal tumours is found in elderly 
and co-morbid people. Not all patients with localised RCC who are fit for 
surgery undergo nephrectomy, but a growing proportion of patients are 
actively surveilled. In addition, first-line options for mRCC and advanced RCC 
are on the verge of a major change: the role of cytoreductive nephrectomy is 
being questioned, and there is a variety of systemic therapies to choose from. 
For finding the optimal follow-up and treatment protocol for each patient, the 
search for an optimal biomarker is of greater interest than ever. The growing 
understanding of immunogenic and molecular mechanisms of RCC has led us 
to this moment when we finally might be able to find truly predictive 
biomarkers or prognostic systems. 
6.1 SUSPICIOUS MASS IN KIDNEY: ANY CHANGES IN 
TREATMENT PATTERNS? 
The tumours suspected of being RCC are a major dilemma and pose serious 
questions: when to follow-up, is biopsy needed, when to operate and will the 
patient survive long enough to benefit from surgery. Our study (I) comprises 
practically all tumours suspected of being RCC in the HUH region. By 
restricting inclusion to tumours, not based on histology but suspicion of 
malignancy, we wanted to address this common clinical challenge: how to 
manage an unknown kidney mass identified radiologically. According to study 
(I), the proportion of active surveillance increased during the study period, 
although no commonly accepted protocol and admittance criteria exist. To 
support the decision about surveillance or operation, the proportion of tumour 
biopsies taken increased as well. During the study period, we aimed to 
familiarise urologists, radiologists and pathologists with the method. However, 
it must be remembered that RTB comes with morbidity. As it has been stated 
by Uzosike et al., RTB is appropriate only if it will change the treatment (152). 
And, due to tumour heterogeneity, Uzosike et al. does not recommend follow-
up based on biopsy findings in young and healthy patients fit enough to 
undergo PN (152). Tumour seeding, especially when pRCC is concerned, is a 
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minor but existing risk, and it must be balanced against the usefulness of 
information received by tumour biopsy.  
We counted as initial or first-line the treatments delivered during the first 
six months after the diagnosis because sometimes reaching the verdict takes 
time. It is important to note that, based on large studies, it might not always be 
wise to rush on selecting a definite treatment during the first six-month period 
(152, 154) as, reportedly, brief follow-up is considered safe and is needed for 
determining growth rate  (152). Certainly, patients with an elevated growth rate 
need to be considered for active treatment.  
The portion of mRCC diagnosed did not significantly decrease during the 
follow-up, although more incidental tumours were found. Our work, in line with 
other studies, determined that metastatic disease is still diagnosed in up to 20% 
of new RCC cases (2, 17). The rate of systemic treatments delivered have remained 
at the same level, but the rate of CN has decreased steadily. In Finland and 
Sweden, half of the mRCC patients currently receive CN. In the US, however, 
merely 30% of mRCC patients undergo nephrectomy (96). The American authors 
have speculated that the use of CN is lower in black, un-insured, unmarried 
patients and in those treated outside academic centres (96, 216). However, the 
role of CN might be changing. In light of the current data, CN is not being 
recommended for high-risk patients by MKSCC criteria or for intermediate-risk 
patients with progressing disease, despite oncological treatment (217). 
6.2 TUMOUR SIZE, DOES IT MATTER? 
At the time of the study III, anatomic classifications were widely studied and 
complex classifications were invented to add more information about diameter 
(T-stage). The efforts to develop a better nephrometry system are ongoing 
(218). Although many parameters of tumour, such as diameter, depth of 
tumour, location and proximity to hilar vessels and the urinary collecting 
system, do guide the type of nephrectomy chosen, only diameter (T-stage) 
exists in the guidelines (217). We wanted to see if simple invasion could 
outperform the diameter and more complex classifications (PADUA and RTII).  
Invasion, measured as the distance the tumour invades from the surface of 
kidney cortex into the parenchyma, has been previously shown to be associated 
with operation time (219), warm ischaemia time (219), postoperative renal 
function (220) and postoperative complications (63). Our study investigated 
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whether invasion correlates with the type of nephrectomy performed. Invasion 
was superior to other models tested in predicting the type of nephrectomy 
chosen (III). Logically, the deeper the tumour invades, the more complicated 
the surgery becomes. 
To test usefulness of invasion further, we showed that tumour invasion has 
the potential to predict recurrence (unpublished work by author). In the past, 
PADUA score and RENAL nephrometry have been used to predict local 
recurrence after ablative therapies (63, 221), and more complex tumours  
associated with higher growth rate in active surveillance (222). However, we 
found that patients with deeper invading tumours had recurrences more often 
after both RN and PN. Invasion also remained a significant predictor when 
combined with histology, diameter and Fuhrman grade. However, one might 
argue that increased recurrence might be due to unsuccessful surgery, i.e. 
positive surgical margins. As patients with deeper invasion more often undergo 
RN, it might instead be the tumour amenities that cause the recurrence than 
the tumour material left behind. 
No previous studies concerning invasion as a predictor of recurrence exist 
as far as we are aware of. Invasion may have been overlooked as it might seem 
to be a composite of diameter. However, it remained significant in 
multivariable analysis, suggesting that it could have some predictive value on 
its own. It can be hypothesised that, the closer the tumour invades to the hilus 
or pelvis, the more prone it might be to metastasise.  
Another interesting question is whether increased recurrence will translate 
to increased cancer mortality. In our data, there were no indications of this. 
Invasion did lose its significance when combined with Fuhrman grade and 
tumour diameter. According to the data, the majority of the recurrences occur 
within the first three years, and greatest risk for recurrence is within five years. 
Therefore, one could hypothesise that the median follow-up time of 5.6 years 
(67 months) would be enough for showing the effect of invasion on recurrence, 
but it would not be enough to show the true impact on CSS. A study with longer 
follow-up times would be needed to answer this question. 
6.3 S-TATI, SHOULD WE MEASURE IT? 
The main finding in study V was that elevated S-TATI values, both 
preoperatively and postoperatively measured, raised the risk of overall death 
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and death from RCC. Based on our data, postoperative S-TATI seemed to be a 
better predictor of OS than of CSS. This is convincing, as OS is often seen as a 
more significant and robust endpoint since it is not always clear when deciding 
if RCC is the ultimate cause of death or not.  
Against our first assumption, postoperative S-TATI did not predict the 
recurrence significantly (V). There were only 26 N0M0 patients that did have 
recurrence, so it is possible that association might become visible only with 
larger patient populations.  
S-TATI, or serine protease inhibitor 1 (SPINK1), acts as a protector of the 
pancreas against premature activation of trypsin, as an acute phase reactant, 
growth factor and inhibitor of apoptosis (223). In RCC, TATI is detected only in 
cell lines but not in RCC tissue (123), leaving the source of TATI in RCC unclear. 
In colorectal carcinoma, it is hypothesised that TATI has a role as an oncogene 
as well (224, 225). With all these functions, S-TATI has the potential to measure 
malignant behaviour of a tumour. However, having an acute phase reactant, 
such as TATI, as a prognostic marker of cancer poses many questions that must 
be addressed: how to exclude other acute infections, acute tissue damage caused 
by recent operation or impact of renal dysfunction (226). In study (V), we tried 
to address these points by excluding patients with severe renal dysfunction (CKD 
grade 4 to 5) or acute infections and by measuring the S-TATI minimum at three 
weeks after the operation based on previous publications (227).  
S-TATI as a continuous variable seemed to predict mortality better than 
dichotomized S-TATI. Often, a continuous variable is considered to be less 
vulnerable to statistical errors than a dichotomised variable. However, being 
able to give a cut-off value predicting malignancy would be of utmost interest 
for clinicians. From the ROC analysis, the value of 16 µg/l seemed to be the 
best cut-off for indicating malignancy (sensitivity being 62% and specificity 
63%). The same cut-off figure was proposed earlier for RCC (228) and 
colorectal carcinoma (229), and the reference interval of S-TATI in serum and 
plasma was suggested to be 5-15 µg/l (226). However, S-TATI did not excel in 
the ROC analysis, suggesting that using a biomarker with such a pleiotropic 
role might be challenging or even suboptimal for recognising cancer. 
Based on these findings, we could speculate that in the future postoperative 
S-TATI measurements, in a combination with other markers, might be useful 
when selecting the intensity of postoperative follow-up controls but even when 
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estimating if high-risk patients would benefit from adjuvant or neo-adjuvant 
therapy. Räsänen et al. (15) have speculated that TATI might even have the 
potential for becoming a target for cancer therapy in the near future. 
S-TATI is readily available, reproducible and inexpensive, making it a 
clinically applicable biomarker. To gain more information about the marker, it 
might easily be added into preoperative and postoperative laboratory protocol 
for patients undergoing nephrectomy. To properly examine the performance 
of S-TATI as a prognostic biomarker, a large prospective study is needed, and 
our study can be considered as a hypothesis-generating work. 
6.4 LOCALLY ADVANCED, WHO SHOULD BE 
OPERATED? 
We aimed to show that more extended TT would predict worse CSS after 
nephrectomy and thrombectomy, but thrombus level did not reach statistical 
significance when predicting survival (II). In our data, only 9 patients (6%) had 
supradiaphragmatic venous thrombus, and such a limited sample is vulnerable to 
results caused by pure chance. Before our data were gathered, the level of 
thrombus as a prognostic factor had been controversial (172-174), and there were 
speculations that the prognostic effect might become visible only in larger patient 
data sets. Just recently, a large meta-analysis by Gu et al. showed that the level of 
TT is a prognostic factor of CSS and OS for non-metastatic RCC with TT (171).  
The main finding in study II, however, was that patients with RCC and venous 
thrombus with lymph node metastasis had a poor prognosis after nephrectomy 
and thrombectomy. Indeed, the median survival of N1 patients was shorter even 
than that of patients with distant metastases, at 10 months and 18 months, 
respectively. This finding concurs with that of other studies (170, 230). The 
reasons behind this phenomenon are unknown, and possibly the speculated 
hematogenous micrometastasis spread from TT is a less important factor than 
spreading through lymphatic system. In the systematic review by Gu et al., 
positive lymph nodes predicted both inferior OS and CSS (171).   
The question that remains is whether the prognosis would improve by 
removing the pathological lymph nodes. A study by Tilki et al. showed superior 
5-year CSS for N1 patients than our study did (5-year CSS 17.3% for Tilki and 
0% for our population, respectively) (170). Our results might have been 
affected by the low number of N1 patients (n=24). Another difference was that, 
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in their study, all of the N1 patients received lymphadenectomy, whereas in our 
study II, positive lymph nodes might have been biopsied, resected with 
lumbectomy or removed with thorough lymphadenectomy (170). A recent 
study by Tilki et al. determined that up to 10% of clinically node-negative 
patients revealed positive lymph nodes in pathological analysis (231). 
Expectedly, clinically node-negative patients had better survival after 
thrombectomy and lymphadenectomy in Tilki et al.’s study. The important 
question is still unanswered as to whether node-negative patients benefit from 
prophylactic lymphadenectomy in comparison with just being observed until 
lymph nodes become visible in imaging studies. 
Accurate and recent imaging before tumour thrombectomy is essential. Not 
only the level of TT markedly affects the selection of the operating technique, 
but also the personnel and equipment needed and the intensity and length of 
postoperative care. The metastatic state and the lymph-node status as well as 
other prognostic markers should be considered when deciding the treatment. 
In our study, the survival of mRCC patients with TT was surprisingly good. 
Compared with studies that had begun their patient gathering before the 
targeted therapy era, there was a clear survival benefit (170). This could imply 
that operations on mRCC with TT could be more advantageous when combined 
with targeted therapy or novel immunotherapy. Based on our study II, we 
would suggest considering operative treatment for mRCC patients with TT at 
least in the presence of solitary and/or resectable metastases. However, 
considering the poor prognosis of N1 patients, operative treatment as an 
obvious first-line treatment might need to be reconsidered.   
When it comes to non-metastasised RCC with TT, after complete removal 
of tumour material, up to half of the patients experience recurrence in three 
years (232). Unfortunately, adjuvant therapy with TKIs does not have much to 
offer to this group of patients or N1 patients either, as adjuvant therapy does 
not provide an OS benefit according to recent meta-analysis (187). This group 
of patients showed a DFS benefit after adjuvant therapy however, but it is 
unclear if this would translate to OS benefit in the future. The possible benefit 
of adjuvant therapy must always be weighed against the risk of adverse effects.  
The previously noted poor prognosis of patients with pRCC with TT 
compared with ccRCC (172) also existed in our study II. Being clearly less 
common than ccRCC, pRCC patients are often excluded from clinical trials for 
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cancer drugs (233, 234). Due to the lack of therapies targeted to pRCC, these 
patients receive medication targeted for ccRCC, albeit pRCC does not respond 
equally well (235). To improve the prognosis of locally advanced and 
metastasised pRCC patients, we need medical trials targeted specifically for 
pRCC patients. 
6.5 METASTASISED RCC AND MODERN SYSTEMIC 
THERAPY, ANY POINT OF OPERATING? 
Up to 200 retrospective studies about metastasectomy exist, but the patient 
populations are often small, and these are mainly from the cytokine era. As a 
handful of studies are from the targeted therapy era, there are arguments that 
the effect of targeted therapy might diminish the shown effect of 
metastasectomy on survival. Amongst these retrospective studies, our study IV 
has large patient population and is from the targeted therapy era. 
Concurrent with our work (IV), recent works by Sun et al. and Lyon et al., 
suggest that the survival benefit of metastasectomy is consistent also in the era 
of targeted therapy (236, 237). A large database study by Sun et al. with 1,976 
patients undergoing metastasectomy suggested that metastasectomy is 
associated with 17% decline of all-cause mortality (236). This propensity score-
matched analysis showed that patients who underwent metastasectomy had 
superior OS than patients who did not (median OS: 24.1 vs 18.9 months) (236). 
A more recent study by Lyon et al. revealed all-cause mortality declined by 
nearly 60% amongst patients undergoing complete metastasectomy (237). The 
discrepancy in results might be explained by an inability to assess whether the 
metastasectomy was complete or non-complete leading to all 
metastasectomies being aggregated in a single group in the study by Sun (236). 
Our study IV suggested a survival benefit for patients undergoing complete 
metastasectomy vs patients with incomplete metastasectomy, which is in line 
with other studies (195) (237). However, our survival rates were surprisingly 
good, as the median overall survival was 77 months for complete and 57 
months for incomplete metastasectomy. The increasing use of targeted therapy 
might explain some of the survival benefit compared with that of the study of 
Alt et al. with a median OS of 47 months and 15.6 months for complete and 
incomplete metastasectomy, respectively (197). In Alt et al.’s study of patients 
receiving systemic therapy, only 13% received targeted therapy, while 89% 
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(49/55) in our study received targeted therapy and one patient received novel 
immunological treatment.  
One might argue that the beneficial results from metastasectomy are due to 
selection bias, i.e. only patients with favourable prognosis undergo an 
operation. Although Sun et al. tried to eliminate the effects of potential bias by 
propensity score adjustments (236), in the absence of RCTs, it is always 
possible that confounding factors exist and affect the results.  
When it comes to performance status, patients accepted for clinical medical 
trials (e.g. CARMENA) have to have good performance status (ECOG 
performance score of 0 or 1) (11). It is noteworthy that, in our study, 21% of 
patients had low performance status (ECOG 2-5) (IV). This is markedly more 
frequent than in the study of Lyon et al. (ECOG 2-5: 6%)(237) or the older one 
by Vogl et al. (Karnofsky score ≤80%: 12.1%)(198). When compared with 
patients in the study of Tosco et al. (205), our patients had poorer prognostic 
markers in terms of a longer interval between nephrectomy and metastases, 
solitary metastatic lesions and performance status (42).  
Indeed, considering the poor prognostic features of our metastasectomy 
population, the survival was surprisingly good. We do not have analogous OS 
figures from the current era for comparison, however. Lyon et al. reported only 
CSS figures with a shorter follow-up time, and in the study of Sun et al., median 
OS of 24.1 months for metastasectomy and 18.9 months for no-
metastasectomy were affected by aggregation of complete and non-complete 
metastasectomies. Even the median survival of non-complete resection in our 
study surpassed those achieved with targeted therapy as the median OS of 26 
months for sunitinib was noted, and for the nivolumab-plus-ipilimumab 
group, it was not reached during the median follow-up of 25 months (211). 
Poor prognostic features may have caused the relatively large number of 
patients (71%) recurring soon (RFS ≤ 12 months) in our study IV. This 
emphasises that patient selection for operative treatment is of utmost 
importance. Maybe all recurring patients in our study did not personally 
benefit from the surgery, although the survival of the whole population was 
improved. Here, the patient’s preference also comes into question. To find the 
patients who will benefit from metastasectomy, we need better prognostic 
systems and predictive markers. Yet, our study failed to prove the accuracy of 
LU prognostic groups as a tool for stratifying mRCC patients according to their 
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prognosis. As mentioned earlier, our population was different in terms of 
known prognostic factors. However, an accurate prognostic tool has to work in 
all kinds of populations. 
Not all metastasectomies aim for longer survival. In our study, one-third of 
metastasectomies were cytoreductive in nature, and 62% of the operations for 
bone metastases were palliative (IV). In a study by Vogl et al. from the era of 
immunotherapy and IFN-α, 65% of patients had metastasectomy done for 
palliative reasons, i.e. for pain control or maintenance of skeletal integrity 
(198). The authors also pointed out that incomplete resection was a predictor 
of survival. Figure 20 presents a clinical scenario leading to CN. 
   
a)                                           b)                                                  c) 
 
d) 
Figure 20 Incidentally found synchronous liver metastasis of RCC which ended up being 
treated by angioembolisation due to acute bleeding. a) Preoperative CT image: 
16 cm tumour in left kidney. b) Preoperative CT image: Large 6.5 cm metastasis 
in liver. c) Before consultation of urologist, the patient arrived at the ER due to 
stomach pain. Active, life-threatening, bleeding from liver metastasis was noted 
in the CT. d) Emergency angioembolisation was made and stopped the bleeding. 
Liver resection and nephrectomy were planned as the patient had Heng risk 
status of good/intermediate risk. CT images were provided by the HUS urology 
clinic patient archives. 
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Our data concurs with other available data suggesting that metastasectomy 
still plays a part in this era of targeted therapy and check-point inhibitors. 
Apart from palliation, only a subgroup of patients benefits from 
metastasectomy. However, for some patients, metastasectomy offers clearly 
prolonged survival and delays the initiation of systemic treatment. The value 
of time without systemic therapy should not be underestimated as cancer drugs 
come with side effects. Metastasectomy, having acceptable morbidity in 
selected patients, might be gaining popularity as a part of a multimodality 
setting, especially if on-going randomised trials prove its efficacy 
(NCT00918775 and NCT01444807). Before that becomes a reality, however, 
decisions to operate should be done in co-operation with oncologists, and 
appropriate patient selection should be based on the prognostic factors, while 
considering the risks of treatments remains of ultimate importance.   
6.6 BIG OPERATIONS, BIG CENTRES AND BIG RISKS? 
Although the data of studies II and IV included patients with locally advanced 
or metastasized disease and technically challenged surgery, the complication 
rate was not that high. We noted a 30-day complication rate of 34% for 
operations on TT and 36% for initial metastasectomies, similar to the rates 
documented in the literature, but with fewer major complications (169, 238). 
The 30-day mortality was 1% for RCC with TT, being 0% for initial 
metastasectomies, but 0.8% for all metastasectomies, which was in line with 
the literature (169, 238). Patients undergoing CN have had more wound 
complications and more delayed (>90 days) complications after initiation of 
systemic therapy (239), but no differences in 30-day complications or severe 
complications (Clavien-Dindo ≥3) were noted (239, 240). An association with 
metastasectomy complications after commencement of targeted therapy has 
not been ascertained in the era of targeted therapy (238).  
Operating RCC with extensive TT is challenging and has a high risk of 
vascular and major complications, and it is considered as safe when being 
performed in high-volume centres with the help of vascular surgeons, thoracic 
surgeons and anaesthesiologists. Interestingly, in a recent study of Meyer et 
al., no difference in complications of metastasectomy was noted regardless of 
the type of hospital or annual volume of cancer cases (238).  
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The team constellation, knowledgeability and volume of the centre may also 
affect implementing new treatment recommendations into the clinical 
practice. The 2001 EAU Guidelines on RCC stated the final evaluation of 
oncologic efficacy to be uncertain for T1a tumours (241). However, by the time 
the next fully updated version of the Guidelines was published in 2007, PN had 
already become the treatment of choice for all T1a tumours (242). Accordingly, 
the rate of PN increased markedly during the study period: in 2006-2008, only 
57% of T1a patients underwent PN, but in 2012-2014, 87% did (III). The low 
adherence to guidelines in the first years of study might seem disheartening in 
a high-volume centre such as ours. At the time of the study, renal surgery was 
seen as a common operation suitable for all urologists and residents, and in 
study II, there were 26 urologist and/or residents who performed or assisted 
in 915 operations. Since the days of the study, we have gradually centralised 
the renal surgery to a limited number of urologists in our clinic. We assume 
that not only the volume of the clinic matters; we presumably also need high-
volume urologists. In the future, we expect new treatment recommendations 
to be promptly accepted and followed in our clinic. 
6.7 LIMITATIONS 
The limitations of these studies (I-IV) include the nature of retrospective, 
single-centre study design, meaning that the results might not be generalizable 
to other populations. Due to the centralised system, only sporadic patients are 
missing from these patient cohorts gathered from the district of 1.67 million 
people. Despite the comprehensive patient cohort, for rare diseases, the 
volume of patients was too limited to offer sufficient distribution of patients 
amongst different categories. The unequal distribution of patients between LU 
prognostic groups (IV) and groups by level of TT involvement (II) may have 
affected our results. 
No re-evaluations were done concerning the pathological examinations. At 
the beginning of these study periods (I-V), pathologists did not use any 
structured report form, which might mean that some information about 
necrosis, rhabdoid features, and sarcomatoid features might be missing from 
reports. As a structured report is now commonly used, this format requires that 
the pathologist always comment on these features. The ECOG performance 
status, CCI and Clavien-Dindo complication score should be determined at the 
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time of diagnosis or complications, but in these studies, many of them were 
assigned retrospectively by investigators. The limitations of these studies also 
include the continually improving imaging accuracy, meaning that the quality 
of imagines done at the beginning of study do not match the standards of today.  
The main limitation of study V was minor and heterogenous patient data, 
which might have lessened the value of S-TATI as a prognosticator. We had to 
exclude many patients from the final analyses due to a disease of benign origin 
or urothelial carcinoma.  
Unfortunately, at the time of study planning, neutrophils, lymphocytes and 
calcium were not seen as valuable prognostic markers for RCC in our clinic and 
were not routinely measured. This precluded us from including the Heng score 
or MKSCC nomogram in study IV. While in study V, comparing S-TATI with 
other inflammation markers with proven prognostic significance, as the 
neutrophil-lymphocyte ratio, would have been of significant interest. S-TATI 
was not measured repeatedly, which would have been relevant, especially 
considering the cases that recurred. 
6.8 RCC, WHAT’S AHEAD? 
Since the beginning of these studies, the treatment of RCC has changed 
substantially as we are moving from targeted therapy to novel immunotherapy. 
In addition, the substance of our work, the patient cohort, is changing. The 
patient population with small renal tumours is getting older, frailer and more 
prone to co-morbidities (I) (243, 244). Web-based, easy-to-use prediction 
nomograms, similar to the  ones for prostate cancer created by MSKCC (245) 
to predict the risk of death and cancer-specific death of an individual patient, 
are eagerly anticipated. One key issue for creating prediction tools is how to 
define frailty. Co-morbidities or even performance status systems (i.e. ECOG) 
do not paint the whole picture of the recovering ability of an elderly person, 
while thorough geriatric questionnaires are often too detailed to use in daily 
practice.  
The increase in incidentally found small tumours has not led to a decrease 
of newly diagnosed mRCC. Being the most lethal urological malignancy, but 
curatively manageable when diagnosed early, RCC screening seems a credible 
option. At the moment, no recommendations against or for RCC screening 
exist. Since RCC has a relatively low incidence rate, screening subpopulations, 
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i.e. patients older than 70 years of age, might be more rewarding while they are 
at an increased risk for high-stage and high-grade renal carcinoma (246) 
The potential effect of screening is based on the assumption that early 
treatment should yield better survival. Indeed, the increase of RCC mortality 
has stabilised or even declined in recent years in many countries in 
Scandinavia (16). However, treating small incidental tumours may not lower 
overall mortality, which is more dependent on aging, frailty and co-morbidity. 
Fenton et al. estimated a sojourn time for RCC (mean duration of the 
detectable preclinical period) to be from 3.7 to 5.8 years, meaning that 
screened RCC of people under 65 would usually progress to clinical diagnosis 
during their life (247). 
In one recent meta-analysis, which has presumably underestimated the 
true prevalence of histologically proven RCC, Rossi et al. (248) speculated that 
screening of RCC might even be as effective as the screening of abdominal 
aortal aneurysm or colorectal cancer, both of which have established screening 
programmes in UK. However, due to the different nature of diseases, 
comparing diseases is spurious. While healthcare costs are continuously 
increasing, screening cannot just be effective, but cost-effective as well. Rossi 
et al. recently published a cost-effectiveness analysis, where ultrasound 
screening seemed to be cost-efficient in 60-year old males (249). We must 
remember that the true prevalence of RCC by age/sex is still unknown as 
current figures may underestimate it due to uneven distribution of studies 
worldwide. For screening purposes, there is a need for inexpensive but 
accurate biomarkers, such as the ones measured from urine or blood. 
Cancer treatment has made great progress. However, many of these 
treatments, such as metastasectomy, CN and many systemic therapies are 
effective only for some patients with good prognostic markers or for patients 
expressing specific biomarkers predicting responsiveness to therapy. In the 
future, the genetic and molecular analysis of tumour might be the base for 
treatment. This author believes that nephrectomies and metastasectomies 
might be needed in future not only for tumour histology but also for receiving 
enough tissue material to test the effects of various drugs on heterogenous 
tumour tissue (250).  
In the future, treatment of RCC, especially when locally advanced or 
metastasised, has to be customised concerning cancer amenities, patient 
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derived factors, possible side effects of treatments and treatment efficacy. To 
offer the surgical and oncological treatments in the right sequence, we will 
need tight collaboration between urologists and oncologists. When planning 
the personalised treatment, we have to bear in mind the goal of each patient 
whether it is the longest survival or maintaining best possible QOL. This means 
that multidisciplinary teams should not just consider the tissue specimen but 
also take into account the whole individual affected by the disease.  
Multiple tissue-based predictive biomarkers for metastatic ccRCC are 
emerging currently, but need to be validated, while non-ccRCC lacks 
candidates for potential biomarkers. No other prognostic marker is superior to 
tumour stage, despite the fervent search for a perfect prognostic marker. In the 
future, all potential prognostic markers should be compared with the TNM 
stage, the most substantial conventional prognostic marker, to prove their 
accuracy. The anatomical, histological and clinical prognostic factors 
combined have reached their ceiling in prediction accuracy (251). What we 
should be looking for is a combination of clinical and histological markers 
together with laboratory parameters, as genetic, molecular and tissue-based 
markers, to obtain more precise prognosticators. 
6.9 FUTURE SCIENTIFIC CONSIDERATIONS 
Over the past few decades, several biomarkers have been studied to estimate 
the prognosis of RCC. We are aiming to use the Helsinki Biobank RCC tissue 
samples to test a variety of known histochemical and immunohistochemical 
prognostic tissue markers in tumour microarrays (TMAs). To determine if any 
markers seem to predict recurrence or death, we are comparing them with 
prognostic data from the Helsinki University Kidney tumour database.  
For this thesis, I ran further analyses to test the performance of tumour 
invasion in predicting RCC recurrence. In these preliminary analyses, invasion 
also seemed to be an independent prognostic marker when compared with 
tumour diameter, histology and Fuhrman grade. This is an important result as 
we can easily measure invasion using CT images. I intend to rerun the analyses, 
with additional clinical parameters, e.g. tumour necrosis, to see if this effect 
remains and to see if adding invasion to well-established prognostic scores, as 
the Leibovich score, would improve the accuracy of prognostication. Indeed, it 
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would be valuable to see if the effect of invasion is lost when a tumour becomes 
locally advanced, i.e. reaches the perirenal fat or pelvis. 
One limitation of my studies (II, IV) was the small size of patient 
subcohorts. Despite the fact that our hospital is amongst the largest RCC 
centres in Northern European countries, when it comes to rare diseases as 
supradiaphragmatic TT, we do not have enough patients to run reliable 
analysis. After the initiation of my substudies, new collaboration groups for 
RCC researchers have been founded. Our study group is active in FinnKidney, 
a Finnish working group, and in NORENCA, a collaboration of RCC 
researchers in Nordic countries. A multicentre approach allows us to enrol 
more patients, making it possible to study rare diseases as well as to compare 
differences amongst different centres or nationalities. 
Preoperative and non-invasive prognostic prediction methods are urgently 
needed to either replace or to be used with renal tumour biopsies. Today, the 
prognostic nomograms rely heavily on histology, which is only gained by 
invasive methods. As RCC patients get older and frailer, to operate or not to 
operate becomes a fundamental question. Despite the small and heterogenous 
patient number, TATI expression seems to be associated with adverse 
prognosis. In the future, it would be of value to use serum and urine samples 
of RCC patients from the Helsinki biobank to test the prognostic accuracy of 
promising up-to-date biomarkers. 
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7 CONCLUSIONS 
On the basis of the present studies, the following conclusions can be drawn 
concerning the RCC patients treated surgically at Helsinki University Hospital. 
1. RCC patients generally are getting older and more fragile. We are 
finding smaller and smaller tumours and more asymptomatic 
tumours. Mini-invasive treatments are becoming more popular, and 
we are treating more patients with active surveillance and taking 
biopsies of tumours more often. The proportion of newly diagnosed 
M1 patients did not change during the surveillance period. A shift in 
oncological treatments from targeted therapy to immunotherapy was 
not yet clearly observed in these studies. The number of CNs has 
declined. 
2. The level of TT seems to be a prognostic marker only in large cohorts. 
The improved survival and feasible complication rate of mRCC 
patients after nephrectomy and thrombectomy makes operating on 
mRCC patients with TT a reasonable choice in the era of targeted 
therapy. The survival of the patients with pRCC and TT as well as N1 
patients has been dismal. 
3. Parenchymal invasion as well as diameter outperformed the more 
complex classifications, PADUA and RTII, in predicting the type of 
nephrectomy performed. Invasion seems to be an independent 
prognostic marker of recurrence, also when compared with tumour 
diameter. 
4. Survival of all mRCC patients after metastasectomy was favourable, 
although the patient cohort lacked prosperous features for survival 
after metastasectomy. Assumedly, survival was superior for patients 
with complete metastasectomy compared with incomplete surgery. 
Complete metastasectomy led to longer systemic treatment-free time 
as well. Previously published LU prognostic groups did not predict the 
survival in this patient cohort. 
5. S-TATI was able to predict CSS and OS as well as longer therapy-free 
intervals. The earlier suggested cut-off point of 16 µg/l seemed to be a 
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sensible cut-off value for survival. To validate these results, S-TATI 
should be investigated in large, prospective series, and the 
confounding effects should be addressed more thoroughly. 
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